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Ulcerative Colitis (UC) is a chronic, inflammatory disease of the colon that has a relapsing-remitting 
characteristic. The disease management consists of prolonging periods of remission and reducing 
relapse frequency. There is currently no universally accepted definition of remission in UC. There are 
different methods of establishing if a patient is in remission, but the lack of definition and knowledge 
make it difficult to know which method to use. The majority of these methods are poorly described for 
remission patients representing a substantial knowledge gap.  
This thesis explored the remission term by investigating the mucosal transcriptional profile in UC 
remission patients and the utility of histology and transcripts as evaluation modalities. The project was 
a part of the Advanced Study of Inflammatory Bowel disease (ASIB) prospective study at the 
University Hospital of Northern Norway, Tromsø. All patients were recruited from August 2013 to 
April 2016 and they have given written consent to participate in the study.  
We found that several of the gene transcripts investigated were differently expressed in UC remission 
patients in comparison to healthy controls. These genes were largely related to pro-inflammatory 
mechanisms and barrier dysfunction, indicating that despite an apparent normal mucosa in endoscopy, 
the mucosa differed on a transcriptional level. We then investigated if histology could detect 
inflammation and consistently classify a patient as in remission using the different scoring indices. 
The results showed that histology could detect inflammation invisible to the naked eye, but the 
histologic scores varied too much to be accurate in a categorical classification. The main source of 
variance was the histologic raters. Lastly, we investigated if any of the clinical, endoscopic, histologic, 
or transcriptional variables could predict impending relapse. The results showed that patients with a 
low ratio between two transcripts had 5.3 times higher risk of relapse. Histologic factors did not turn 
out to be predictive of relapse. Clinical and endoscopic factors were promising but ultimately not 
significant, possibly hindered by low pow er. 
The conclusion was that several gene transcripts were differently regulated in UC remission patients 
compared to healthy controls. Some of these may be able to predict relapse and have potential use as 
biomarkers to improve the current treatment regimes. Histology might be used as an aid in tailored 
treatment but should not be used as a hard endpoint due to high variance. The transcript ratio must be 






Ulcerøs kolitt (UC) er en kronisk, inflammatorisk sykdom i tykktarmen som har uregelmessige 
perioder med høy og lav inflammatorisk aktivitet. Behandling forsøker å opprettholde lav-
inflammatoriske perioder samt minimere antall tilbakefall til perioder med høy aktivitet. Periodene 
med lav aktivitet kalles remisjon og per nå finnes det ingen anerkjent definisjon av remisjon. Det 
finnes mange metoder å fastsette remisjon på, men mangel på definisjon og kunnskap gjør det 
vanskelig å vite hvilke som er nyttige. De fleste av disse metodene er dårlig beskrevet hos remisjons 
pasienter, noe som utgjør et kunnskapshull. 
Denne avhandlingen utforsker vi remisjonsbegrepet ved å undersøke tarmslimhinnes genutrykk 
(transkript) profil hos UC remisjonspasienter og sammenligner den med kontroller. I tillegg evaluerer 
vi verdien av histologi og transkripter i vurderingen av remisjon. Denne studien er en del av Advanced 
Study of Inflammatory Bowel disease (ASIB) prosjektet som går ved Universitetssykehuset Nord-
Norge i Tromsø. Alle pasienter ble rekrutter fra august 2013 til april 2016 og har gitt skriftlig 
informert samtykke til å donere biopsier fra tarmslimhinnen.  
Vi fant at flere gentranskripter var uttrykt forskjellig hos pasienter i remisjon av UC sammenlignet 
med kontrollene. Disse genene var i hovedsak relatert til pro-inflammatoriske prosesser og 
dysfunksjon i tarmslimhinnens barriere. Dette viser at til tross for en tilsynelatende normal 
tarmslimhinne ved endoskopisk undersøkelse så er det forskjeller på et transkriptnivå. Videre 
undersøkte vi om histologi kunne detektere inflammasjon og deretter presist klassifisere pasientene i 
remisjon med de mest vanlige skåringsindeksene. Resultatene viste at histologi kan oppdage 
inflammasjon som ikke ses ved vanlig endoskopi, men at det er for stor variasjon i de histologiske 
skårene til at de kan benytte til å klassifisere pasienter. Hovedkilden til variansen var de som vurderte 
de histologiske snittene. Til sist vurderte vi om noen av de kliniske, endoskopiske, histologiske eller 
transkripsjonsvariablene kunne identifisere hvem som fikk tilbakefall. Vi fant at et lavt ratio mellom to 
transkripter gav 5.3 ganger økt risiko for tilbakefall. Ingen histologiske variabler økte risikoen for 
tilbakefall. Kliniske og endoskopiske variabler var på grensen til signifikant, men kan ha blitt 
begrenset av et for lite datasett.  
Konklusjonen er at det er flere gentranskripter er uttrykt forskjellig mellom pasienter i remisjon av UC 
og kontroller. Noen av disse transkriptene er assosiert med økt risiko for tilbakefall, og kan derfor 
bidra til bedre behandling av UC pasienter. Histologi kan være til hjelp i å skreddersy behandling til 
pasientene, men bør ikke være et behandlings mål i seg selv. Transkriptene må valideres i et eksternt 
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1.1 Ulcerative Colitis 
Ulcerative Colitis (UC) is a chronic inflammatory disease and is one of two diseases included under 
the umbrella term Inflammatory Bowel Disease (IBD). The other is Crohn’s Disease (CD) which can 
affect the entire alimentary tract. In contrast, UC affects the colon only.  
1.1.1 Epidemiology 
UC has an increasing incidence world-wide ranging 1-24 cases per 100 000 and an aged-standardized 
prevalence of 7-422 per 100 000, depending on location (1, 2). The prevalence in some places in 
Europe surpass 0.3%. The disease has a peculiar distribution with higher numbers in the northern 
hemisphere compared to the south. After a decade of increasing incidence in the developed countries 
the curve now flattens. Aamodt et.al demonstrated that there is a higher prevalence in urban areas than 
in rural and that the disease is more frequent among higher educated people compared to those with 
the lowest level of education (3). A recent paper found a clear trend that countries with high 
Sociodemographic Index (SDI) have higher prevalence than countries with low SDI (2). An estimate 
from Burisch et al. suggests that IBD has a direct healthcare cost of 4.6–5.6 billion Euros/year (4), and 
this cost is likely to increase as more people are affected and new expensive treatments are introduced. 
There does not seem to be any sex predominance in UC (5).  
1.1.2 Pathogenesis of UC 
The pathogenesis of UC is described as multifactorial where environmental, microbial, genomic and 
immunological factors are of main interest (6, 7). In other words, UC is a disease where a 
dysfunctional immune system responds to a dysbiotic microbiome in a genetical susceptible colon. All 
these factors interact and affect each other resulting in a very complex pathogenesis. 
1.1.2.1 Environmental factors 
The increase of the disease and its epidemiological characteristics suggest a strong environmental 
relationship. The increase in the incidence of UC seen in industrial countries with rising life 
expectancy and improved sanitary conditions gave rise to the “hygiene hypothesis” (8). This 
hypothesis suggests that the decrease in enteric infections and general microbes that previously 
affected the intestines at a young age are necessary to prime the immune system to distinguish 
between commensal and pathological antigens later in life. The results from a case-control study from 
New Zealand support this hypothesis. The researchers found that having a vegetable garden in 
childhood is protective against developing IBD, as the garden functions as a surrogate marker of 
exposure to dirt and dirt bacteria (9). A way of investigating the hygiene hypothesis is to study 
migration from developing countries to industrialized countries where immigrants come from low 
affluent and low health care coverage to higher affluence and general health care coverage. A study 
from Sweden shows that first generation immigrants have decreased risk of developing IBD whereas 
in some groups the second generation has higher risk, suggesting that environmental factors play an 
important role early in life (10). 
An interesting notion is the importance of early bacterial colonization of colon from vaginal delivery 
in relation to the risk of developing IBD. Studies have shown that there is a difference in the 




babies delivered by Caesarion section up to 14 months after delivery (11). Especially the phyla 
Bacteriodetes has a delayed colonization and it plays an important role in priming the immune 
system(12). However, no association is found in a meta-analysis investigating the association between 
mode of delivery and risk of IBD (13).  
Interestingly, the same factors may exert different effects in different geographical groups. A case-
control study from Australia investigated the same risk factors in resident Australians, Middle Eastern 
migrants (MEM) in Australia and a Lebanese in Lebanon control group (14). The results showed that 
the same factors have opposite effects in the different populations. Antibiotics, for example has a 
protective function in the MEM group, whereas in the resident Australian group it is a risk factor. The 
authors attribute this to the difference in prescription pattern. In the Australian group, antibiotics could 
be a surrogate for decreased microbial diversity, whereas in the MEM group, antibiotics could be a 
surrogate for GI-infection and ultimately increased diversity. Microbial diversity is discussed more in-
dept in the following chapter.  
Other environmental factors that have an impact on UC are oral contraceptives, urban living, soft 
drinks and vitamin-D deficiency, all of them increasing the risk (15, 16), whereas breastfeeding, pets, 
and smoking are some of the factors reducing the risk of developing UC (16-19). There is evidence for 
a strong association between the environment and the development of the disease, and that some of 
these associations may involve the microbiome as a causative agent.  
1.1.2.2 Microbial factors 
Bacteria is a natural habitant of the gut and it can reach concentrations up to 1011 to 1012 cells/g of 
stool (20). The microbiome has a variety of functions such as educating the immune system, secreting 
digestive enzymes and repressing pathogenic microorganisms (21). It is estimated that the gut contains 
over 1000 bacterial species with dominance in the phylae Firmicutes, Bacteriodetes, Actinobacteria 
and Verrucomicrobia (21-23). The microbiome of IBD patients is often termed “dysbiotic” (21, 24, 
25). It is an ambiguous term with no clear definitions but can be understood as microbial imbalance or 
maladaptation in the colon, which may be part of the pathogenesis. There is evidence for a dysbiosis in 
UC, but it is less clear whether this is causative or a consequence of the inflammation (26). Antibiotics 
are mentioned as a risk factor for IBD in the westernized population. One reason being the effect on 
the intestinal microbiota and a potential cause for dysbiosis (27-29). 
A well-crafted study with a “multi-omic” approach (metagenomic, metatranscriptomic, proteomic, 
metabolomic and viromic) investigated stool samples collected every two weeks from 132 participants 
throughout one year, and reports small differences between UC patients and normal controls (30). This 
is consistent with previous research which reports that the majority of UC patients have a “normal” 
microbiome, and only a subpopulation of IBD patients differs from their controls (31, 32). In the sub-
population a lower abundance and/or diversity in the phylae Firmicutes, and Bacteriodetes are 
observed, while there is an increase in the Gammaproteobacteria, Proteobacteria and 
Enterobacteriacea (21, 33-35). In addition, a shift from obligate anaerobes towards more facultative 
microorganisms in the IBD microbiome, has been reported (35). 
The microbiological difference in subpopulations may be a result of the different states in UC, where 
patients are either in quiescent or active states of disease. A study investigating the dynamics of the 




samples from healthy individuals. It did not, however, correlate with f-calprotectin which was used as 
a surrogate for disease activity (32). 
A confounding factor when evaluating the difference between states on a taxonomic level is the 
heterogenous functions of bacteria. Because of bacteria’s ability to horizontally transfer genes between 
species, a species function can differ from person to person based on the composition of species in its 
environment. Therefore, a different approach to understand the role of the microbiome is to look at 
metabolic pathways rather than types of bacteria.  
The butyrate metabolism in bacteria promotes T-regulatory cells (Treg) development in the gut and 
enhances the mucus production from goblet cells and strengthens the barrier functions (36, 37). UC 
displays reduced butyrate metabolism (38). A bacterial indol metabolite named indoleacrylic acid is a 
product of the tryptophan metabolism. It promotes intestinal epithelial barrier function and mitigates 
inflammatory responses. Microbes in IBD patients have reduced ability to metabolize tryptophan (39). 
Other community-level shifts in the metabolism are magnesium metabolism and oxidative stress 
resistance. A magnesium importing ATP-ase is enriched in IBD subjects relative to controls, which 
may explain the increased risk of magnesium deficiency in IBD patients (40, 41). Oxidative Stress 
(OS) has a vital role in the immune defence, and it is implicated in UC pathophysiology (42). 
Interestingly, the IBD-associated microbiome has enriched reductase enzymes on a community-level, 
giving it a selective advantage in an OS rich milieu (41). Functional analysis have found a greater 
abundance in the chemical carcinogenesis pathway which suggest that the microbiota may contribute 
to the increased risk of CRC seen in UC patients (43).  
Fungi and viruses are also implicated in IBD, but their significance and contribution are still uncertain 
because of few studies and technical challenges (44). Nevertheless, it is an area that holds much 
potential and will certainly be explored in the future.  
Bacteria in the human colon play a crucial role in both sickness and health. To elucidate their role in 
UC the scientific community must first agree on the best investigation approach to use. New 
technology has increased the number of methods to assess composition, abilities, and functions of the 
microbiome. This has made the results difficult to compare and assemble. 
1.1.2.3 Genetic factors 
UC is not a directly hereditable disease, but there is a genetic component to the disease. This is evident 
by the accumulation of the disease within families. Twin studies from Sweden and Denmark found a 
concordance of about 20% between monozygotic twins compared to 0-4.5% in dizygotic twins 
indicating a genetic factor for the disease (45, 46). A meta-analysis supports this view as it reports that 
12% of UC patients has a family history of IBD (47). Interestingly, the incidence of familial IBD is 
higher with earlier debuts of the disease, suggesting there is a stronger genetic component in paediatric 
UC.  
New technologies such as Genome-Wide Association Studies (GWAS) and Next-Generation 
Sequencing (NGS) have made it possible to prod deeper into the genetical background of UC. About 
200 susceptibility loci for IBD are identified, where at least 23 loci are unique to UC (48, 49). 
Nevertheless, these susceptibility loci and genetic risk factors only account for 20-25% of the 




Genes within several different cellular responses and IBD-related processes are identified. IL23R, 
IL12B and IL10 are some of the genes found to be different in UC patients compared to controls, and 
they relate to adaptive immunity and its regulation (50, 51). CDH1, HNF4A and GNA1 are genes 
found to regulate epithelial functions and have been associated with the disease (52, 53). Different 
human leukocyte antigen (HLA) complexes have also been associated with UC. Especially HLA-DR2 
is thought to be significant for the Japanese population (54, 55). As HLA-complex encodes the Major 
Histocompatibility Complexes (MHC), it is crucial for regulation of the immune system. In broad term 
genes related to ER-stress response, epithelial restoration and cell migration are just a few of the 
processes that have risk loci (56).  
Other facets of the genetics of UC are epigenetics. Epigenetic is the action of regulating gene 
expression by modification of its structure, rather than an alteration of the sequence. This regulation 
can be done through DNA methylations. A study has found that hyper-methylation of genes is 
implicated in homeostasis and microbe defence, and that hypo-methylation of genes is related to 
immune response in UC treatment-naïve patients (57). Methylation of specific genes has also been 
suggested as biomarker for cancer surveillance in IBD patients (58)  
A challenge with genetic variants is that they do not necessarily result in a dysfunctional protein. 
Therefore, all genetic variants must be functionally tested in order to comprehend their significance. 
This is time consuming and sometimes not possible as there is no validated benchmark test that 
predicts functional outcome of gene variants. Overall, allele variants, loci and methylation-status are 
all of importance for the understanding of the pathogenesis of UC.  
1.1.2.4 Immunological factors  
When evaluating the role of immune mediators in UC it is difficult to separate cause and effect. Many 
of the agents presented here are important for the disease but may be a consequence of inflammation 
rather than a cause of the disease.  
The primary defence of the colon is its mucosal layer and the epithelial barrier. Its role is preventing 
microbes from entering the mucosa while allowing immune cells to sample antigens in the colonic 
lumen for immune priming. The priming is necessary to ensure a targeted and swift action if an 
intrusion does happen. The epithelial barrier in UC is thought to be defect, thus giving rise to the 
“leaky gut” hypothesis. The barrier consists of several cell types such as enterocytes, Paneth cells and 
goblet cells. The cells are bound together with proteins allowing regulation of the permeability 
through the barrier. These junctional complexes are named tight-junctions, adherence junctions and 
desmosomes (59). Alteration in the composition of these complexes has been found in IBD. Especially 
Claudin 2 is thought to be a central factor in the dysfunction of tight-junctions in UC (60-62). It is also 
documented an altered composition in the monolayer as mucin producing goblet cells are depleted, 
and there is a reduced amount of mucin even in the un-inflamed mucosa (63).  
The reduced barrier function will result in bacterial peptides entering the mucosa triggering an 
immune response. This response is thought to be an overreaction to commensal antigens. The 
inappropriate response is mediated by immune cells such as neutrophils, dendritic cells, T-cells, B-
cells, and innate lymphoid cells. A difference in response has been suggested to be crucial between 




(64-66). This partition is debated as other studies have not found any difference in the type of T-cell 
expression between the diseases (67, 68). 
Innate lymphoid cells (ILC) are thought to be an early instigator of disease. They are in function and 
phenotype similar to T-helper cells but lack rearranged specific antigen receptors. ILCs bridge the 
innate and adaptive immune system, sensing environmental changes and responding by secreting 
cytokines that activate the adaptive immune system. They can also present antigens on MHCII-class 
proteins, but with lower efficiency than professional antigen presenting cells (69). Three main subsets 
of ILC reflecting the function for Th-subsets are identified (table 1) (70). Note that there is plasticity 
between the subset based on the cytokine environment.  
ILC3 has been frequently investigated in animals and is thought to be central to UC pathology. It 
possesses both the ability to aggregate and to ameliorate 
inflammations. The pro-inflammatory mechanisms occur 
through production of the pro-inflammatory cytokines IL17, 
IFNG and GM-CSF in response to IL23 and IL1B (71, 72). 
There is also evidence for ILC3 to produce IL22 in response to 
IL18 and IL21, and thereby inducing production of mucin and 
pro-inflammatory molecules in epithelial cells (73-75). This 
response is protective in certain situations of colitis, but in 
situations of on-going inflammation it exacerbates due to 
increasing chemo-attractants and stress response in the 
epithelial cells (76).  
T-cells are mentioned as important players in the disease. Both CD4+ and CD8+ T-cells are found to 
be increased in IBD intestines (77). While CD8+ T-cells are the effector cells, CD4+ cells are most 
frequently investigated in IBD. Five subsets of T-helper cells are now identified and thought to be 
relevant in IBD (TH1, TH2, TH9, TH17 and Treg). 
TH1 is important in the protection against infectious pathogens, and they produce mainly IFNG and 
TNF activating macrophages and cytotoxic CD8+ cells in an IL12 dominant environment (78). TH1 
cells are considered to play a more important role in CD pathology than in UC pathology. This is 
evident as there are small amounts of IFNG and its transcriptions factor (TBX21) in UC. In addition, 
treatment with anti-IFNG has not been successful in UC (79-81).  
TH2 cells are in charge of defending the host against helminth infections (82). UC is described to be 
atypical-TH2 dominated. Atypical, because of the lack of IL4 presence, which is considered a typical 
TH2 cytokine. Nevertheless, the presence of IL5, IL13 and its transcription factor GATA3, suggest 
that TH2-like cells are major players in UC (61, 65, 83). TH2 immunity also plays a role in other 
diseases such as asthma and atopic dermatitis.  
TH9 is a novel contributor to UC pathology. It is recognized by its transcription factor SPI1 (PU.1) 
and expression of IL9 cytokine (84). IL9 is found to affect the epithelial barrier negatively by 
disturbing tight junction proteins and preventing epithelial regeneration (85-87). It is believed that IL9 





ILC1 TBX21 IFNG  and 
TNF 
ILC2 GATA3 IL4,IL5, IL9, 
and IL13 
ILC3 RORC IL17, IL22, 
GM-CSF, and 
IFNG 




TH17s’ role in IBD is difficult to ascertain due to its plasticity and its dichotomous role in IBD. It is 
found to be increased in UC patients in comparison to healthy controls (89). It is identified by its main 
transcription factor RORC and its IL17 secretions. It is induced by TGFB1, IL1B and IL6, and it 
requires IL23 to maintain its differentiation (90). GWAS studies have found genes related to TH17 to 
be enriched in IBD (48). It exhibits both tolerogenic and pro-inflammatory properties. TH17 can in 
presence of certain infections transform into TH1 and produce IFNG. Conversely, during resolutions 
of inflammations it can transdifferentiate into IL10 producing Tregs (91). These multiple abilities 
make it difficult to investigate TH17, but all evidence point to it being a substantial player in the UC 
pathology.  
T regulatory cells (Treg) are anti-inflammatory players in UC. It is a CD4+ immune cell identified 
by transcription factor FOXP3. Its role is thought to dampen inflammation through production of the 
anti-inflammatory IL10, which supresses the development of pathogenic macrophages and TH1 cells 
(92, 93). Another cytokine central to Tregs is the anti-inflammatory cytokine Transforming Growth 
Factor Beta 1 (TGFB1). It is produced by mature Tregs and induce Treg differentiation, as well as 
inhibit differentiation of T- and B-cells (94, 95). In addition to the anti-inflammatory effect, it is found 
to contribute to fibrosis in UC (96, 97). Consequently, it is proven to be upregulated in UC patients 
compared to controls (98).  
Central Cytokines 
The immune cells exert some of their effect through signalling molecules called cytokines. Therefore, 
some of the central cytokines for UC will be reviewed.  
Tumour necrosis factor (TNF) is a central agent in immune defence and inflammation. Its role is 
primarily pro-inflammatory as it is secreted by innate defence cells such as dendritic cells and 
macrophages. TNF activates adaptive defence cell as well as promoting other pro-inflammatory 
effects such as impaired barrier function, angiogenesis and hypervascularization (99). It also exerts its 
effect on effector T-cells where it prevents apoptotic signals and thereby prolonging their effective 
periods (99). A testament to the importance of TNF is the effect of anti-TNF treatment on UC patients, 
where it is found to lower colectomy rates and steroid free remissions (100, 101).   
IL1B is a part of the IL1 family of cytokines (other members are IL1A IL18, IL33 and IL36) and it is 
primarily thought to be proinflammatory in IBD. In UC, it is found a lower ratio of the IL1-R 
antagonists to IL1, which indicates increased signalling and effect of IL1 (102). In an animal model 
with H. hepaticus-triggered intestinal inflammation IL1B augments recruitment of granulocytes and 
activated ILCs. IL1B is also thought to be induced by Pathogen Associated Molecular Patterns 
(PAMP) signalling through a cytosolic molecular complex called NLRP3 inflammasome (103). 
IL6 is another important proinflammatory cytokine. It is expressed in both myeloid cells and acquired 
immune cells such as Th2 and Th17. As TNF, it shares the effect of inducing other pro-inflammatory 
cytokines and preventing T-cell apoptosis, but unlike TNF, trials with anti-IL6 agents have not proven 
efficient as IBD treatments. The anti-IL6 drug Tocilizumab has showed efficacy in TNF refractory 
moderate to severe CD patients but struggled with high rate of adverse effects such as abscess 




IL10 is one of the central anti-inflammatory cytokines. It exhibits its effect by suppressing pro-
inflammatory production by Antigen Presenting Cells (APC) and inducing anti-inflammatory 
macrophages (106, 107). Increased levels of serum IL10 are identified both during active and inactive 
UC, suggesting that it is not able to contain the inflammation in the active phase, but is necessary for 
resolution of the disease (98, 108). Association between an IL10 single nucleotide polymorphism and 
IBD has been identified in a GWAS study, underlining the importance of IL10 for disease resolution 
(48). 
IL23 belong in the IL12 family and shares a common subunit (p-40) with IL12. It is considered 
proinflammatory and IL23 is necessary to stabilize and maintain Th17-cells. IL23 is produced by 
sentinel tissue such as dendritic cells and macrophages in contact with antigens from the 
microenvironment. It augments TNF production and induces ILC3 to produce IL17 family cytokines 
(IL17A/F and IL22). Ustekinumab is a drug for induction and maintenance treatment and it targets the 
p-40 subunit and thereby blocking both IL23 and IL12 (109). There is currently no pure anti-IL23 
agent approved for UC, but several trials are ongoing (110).  
IL33 is a part of the IL1 family and it is a new and interesting cytokine in UC. IL33 has been 
proposed to have dualistic properties. It is found to be upregulated in inflamed mucosa especially in 
epithelial cells (111-113) and believed to function as an “alarmin” that rallies the colonic immune-
defence (114). In contrast, it is also believed to ameliorate the inflammation through macrophage 
modulation (115) and is found to be up regulated in remission compared to healthy individuals (81). 
TGFB1 is an anti-inflammatory and pro-fibrotic cytokine produced by mature Tregs. Its overall 
function is to suppress immune response to the luminal microenvironment and promote immune 
tolerance (94, 116). TGFB1 is also found to promote collagen production by myofibroblasts (117) 
There is an increased expression of TGFB1 in active UC (118, 119). Interestingly, TGFB1 is found to 
enhance barrier function through regulation of epithelial tight-junctions via maintenance of Claudin-2 
and Occludin levels (120). Several animal knockout models have proved the negative consequences of 
not having TGFB1 (121) 
It is worth remarking that although there is a strong focus on a single cytokine or cell, the UC 
pathogenesis is far too complex to be explained by one immunological factor only. Historically, the 
technology has limited the research to focus on one subject at the time. With the introduction of high 
throughput sequencing and mass spectrometry, it is now possible to investigate a more complex set of 
factors. This will be of great aid in the further unravelling of the UC pathogenesis.   
1.1.3 Symptoms and signs of UC 
UC affects primarily the colon and the main symptoms are bloody stools, abdominal pain and 
diarrhoea. About 6-30% of UC patients may also have extra intestinal manifestation such as primary 
sclerosing cholangitis, ankylosing spondylitis, and iritis/uveitis (122, 123). After onset of symptoms, 
UC usually progresses over several weeks and can lead to fatigue, weight loss and anaemia. There are 
several clinical scoring methods to help evaluating the severity of the disease. The Mayo clinical score 
(Table 2) was developed during a drug trial, and a high score when diagnosed is a negative prognostic 
factor (124, 125). The natural course of the disease is relapsing-remitting which means that there are 
periods of few symptoms alternating with periods with more severe symptoms. The Ibsen study 




the disease and milder symptoms as time progressed (126). Unfortunately, 37% of UC patients in the 
study experiences a relapsing-remitting course continually throughout the follow-up time of 10 years. 
1.1.4 Treatment and clinical outcome 
Clinical courses of UC tend to get less severe over time, but there are two severe outcomes, colectomy 
and Colon-Rectal Cancer (CRC). About 15% of all patients with UC ends up with a colectomy, and 
the major reasons are chronicity and uncontrollable inflammation (127). The risk of CRC has with 
modern treatment and follow-up programs been substantially reduced and is approaching the general 
background risk for CRC (128, 129). However, in certain subgroups like those with long duration, 
primary sclerosing cholangitis, and uncontrolled inflammation the risk is still elevated (130). The 
treatment for UC is a step-wise procedure where the clinical response determines if escalation to more 
potent drugs is necessary. The extent and severity of the disease will guide the physician in choice of 
medication to start with. The first step for induction of remission in mild to moderate UC is 5-ASA. 
Both oral and topical formulations are available, but about one third of the patients does not respond to 
5-ASA alone (131). With lack of improvement, a step up to oral steroids such as Budesonide is 
recommended (132-134). In patients with moderate to severe UC, oral systemic steroids such as 
Prednisolone is appropriate (132, 133). About 16-33% does not respond to steroids and some become 
steroid dependent (135, 136). In patients who are refectory to steroids or have become steroid 
dependent, addition of thiopurines or, alternatively, a switch to anti-TNF treatment in combination 
with thiopurines or methotrexate is recommended (132, 133).  
Although anti-TNF treatment has greatly improved the patient care, about 30-50% of UC patients does 
not respond to anti-TNF treatment and about 30% loose the effect after the first response (137-139). 
There are other biological drugs such as anti-A4B7-intergrins (Vedolizumab), anti-IL12/IL23 subunit 
(Ustekinumab) and antibodies targeting the JAK/STAT pathway (Tofacitinib) (109, 140, 141).  
After induction of remission, maintenance treatment is needed to avoid relapse. 5-ASA is the first 
choice followed by thiopurines and/or anti-TNF treatment (132-134). There is currently no 
recommendation of treatment length for any of the medications used in maintenance treatment. One 
study has investigated the relapse rate for people in long term remission (> 1 year) on Mesalazine 
maintenance treatment. They found a need to maintain treatment up to 2 years after induction of 
remission, but after 2 years there is no difference in relapse rate between drug and placebo (142).  
Treatment strategies are treat-to-target and the target is remission. What constitutes remission is 
heavily debated and is reviewed in separate chapters, but in general terms it is normalization of bowel 
movement, no rectal bleeding and near to normal endoscopic appearance of the mucosa (143, 144). 
Currently about 43% has a relapsing and remitting course during the first year after diagnosis and 16% 
has relapse after cessation of biological treatment (145-147). In a 10-year perspective about 67-83% 
relapses depending on the clinical situation (126, 148). This indicates a potential for improving disease 
management, and one way of improving is to have a clearer target, i.e. a better definition of remission. 
Another important aspect of UC treatment is the medical non-responders. With increasing numbers of 
possible therapies there is a search for markers that can identify those who will benefit from a certain 
medication and those who are at risk of severe outcome and complications. This approach is termed 
personalized medicine and aims to tailor treatment to the individual patient based on multidisciplinary 





1.2.1 Remission definitions  
UC is a disease with periods of active disease with heavy symptoms, followed by periods of fewer 
symptoms. The later periods are labelled remission, a term without a clear definition. As knowledge of 
the disease and technology have progressed, the use of the term remission has changed. Initially, the 
term for symptomatic improvement or relief, as it was the best one could achieve with the drugs at that 
time. With new drugs and better endoscopic equipment, normalised mucosal appearance has been 
established as a positive predictor of outcome and was included in the remission evaluation (151). 
This gave rise to a new term called “mucosal healing”, meaning an endoscopic near to normal mucosal 
appearance (152). Lately, several new remission terms are introduced, such as “deep remission”, 
“immunological remission” and “histologic remission” (153, 154). One reason for the new ways of 
defining remission is the discovery of new modalities for predicting a beneficial outcome of the 
disease. As endoscopy proved to benefit the UC management other modalities such as histology, 
serum markers or genetical markers could lead to further improvement. With each of these new 
modalities follow multiple new scoring indices to aid the evaluation. Therefore, it is no surprise that 
confusion arises and consequently heterogeneity in the use of the remission terms. Boal et al. report 
this heterogeneity and attribute it partly to the large number of different scoring indices for UC (152). 
Ma et al. highlight in their systematic review of 83 randomized controlled trials (RCT), that the 
heterogeneity makes it difficult to compare trial results as 50 different definitions of remission or 
response were applied(155).  
Another side of the remission debate is the issue of clinical-dependent remission criteria, meaning that 
different settings may have different markers for remission. A patient with ongoing biological 
treatment may have one marker for long term remission and thus a physician can de-escalate 
treatment, while another patient who is already in remission may have another marker for imminent 
relapse and should therefore prophylactically escalate treatment. Both these markers need to be 
considered when defining remission. 
In the following sub-chapters important remission factors within each modality, including the most 
acknowledged scoring indices, will be reviewed. The remission term will exclusively be used for the 
clinical setting of de-escalation of treatment while others will be mentioned as relapse markers.  
1.2.1.1 Symptomatic factors 
The disease presents itself through symptoms, and for the patients the symptoms are their main 
concern and meter for disease activity. Therefore, any definition of remission must be founded on 
absence or minimal amounts of symptoms. For a disease with several symptoms, it may be difficult to 
ascertain which symptoms to include in the remission evaluation. If too many symptoms are included, 
the remission state will be unachievable and lead to over-medication. To include too few or wrong 
symptoms will lead to undertreatment. Currently, the main symptoms for UC activity evaluation are 
stool frequency and blood in stool. This is reflected by the fact that most guidelines recommend a 
normalization of these symptoms as a minimum remission criterion (132, 134, 156). Consequently, the 
three most applied symptomatic scores, Ulcerative Colitis Clinical Score (UCCS), Simple Clinical 





 Mayo Clinical Score (Mayo score is a composite score for both endoscopic factors and symptoms, but 
its widespread use warrant inclusion), evaluate these 
symptoms (125, 157, 158). Scoring indices are applied to 
simplify the evaluation by making a patients’ subjective 
symptoms more objective in order to establish a discerning 
cut-off value between active and remission state. 
Interestingly, in all three scores only two symptoms are 
assessed, stool frequency and rectum bleeding. Likely, to 
amend for limitation of evaluating a complex disease by only 
two symptoms, two of the three scores have a subjective 
“physicians’ evaluation” grade. It is not until recently that 
Patient Reported Outcome (PRO) has become a focus and a 
source for evaluation of treatment response and endpoint in 
trials (159). Patient Reported Outcome Measures (PROM) is 
a tool developed to circumvent the physician subjective 
interpretation of the patients’ symptoms. There are few 
PROMs developed for UC and even fewer are commonly 
applied, but Bodgers IBD-control is a PROM simple to use in 
clinical practice (160).  
1.2.1.2 Endoscopic factors 
 There are discrepancies between the symptomatic scores and 
endoscopic findings (161-163). Despite being almost 
asymptomatic, many patients display signs of inflammation 
in the colon. “Mucosal healing” is a term for mucosal 
appearance during endoscopic investigation. It is most often 
defined as Mayo Endoscopic Score of 0 or 1 (MES, Table 
2).Shah et al. report in a meta-analysis that «mucosal 
healing» has improved outcome versus patients with 
endoscopic signs of inflammation (164). From the plethora of 
endoscopic indices the most applied for UC are the 
endoscopic component of the Mayo Score and Ulcerative 
Colitis Endoscopic Index of Severity (Table 3), but only the 
latter is validated (125, 165). There is one other validated 
score, the Ulcerative Colitis Colonoscopic Index of Severity (UCCIS), but it is not widespread in the 
clinical practice due to its complexity (166). There are differences between the scores, but all of them 
evaluate vascular pattern, ulceration/erosion and bleeding. In a remission setting most scores allow 
minor feature of inflammation such as a MES of 1 or a UCCIS of 2. There has been a recent change 
towards only allowing a remission patient to have a MES score of 0 as it has better outcome (167, 
168).  
Stool frequency 
Patient reporting a normal 
number of daily stools 
0 
1-2 more stools than normal 1 
3-4 more stools than normal 2 
≥5 more stools than normal 3 
Rectal bleeding 
None 0 
Blood streaks seen with stool 
less than half of the time 
1 
Blood with most stools 2 
Pure blood passed 3 
Endoscopic findings (MES) 
Normal or inactive colitis 0 
Mild friability, erythema, 
decreased vascularity 
1 
Friability, marked erythema, 
absent vascular pattern, erosions 
2 
Ulcerations and spontaneous 
bleeding 
3 
Physician global assessment 
Normal 0 
Mild colitis 1 
Moderate colitis 2 
Severe colitis 3 





Subjectivity in evaluation will challenge reliability and coherent rating in endoscopy. Features 
representing severe inflammation prove to be easier to evaluate than near to normal mucosa (169, 
170). Therefore, the 
evolution of remission 
investigation needs to delve 
deeper into the mucosa in 
order to discover signs of 




Histology has a long history 
in the diagnosis of UC, and 
the earliest score was 
developed by Trulove and 
Richards in 1956 (171). 
Therefore, it is surprising that 
histology is not more often 
included in the daily clinical 
practice of UC. Many 
guidelines identify histology 
as valuable in disease 
evaluation, but with the 
current levels of evidence, it 
is not recommended as a 
treatment target or a factor for 
remission (132, 144). This is 
likely to change, as several 
histological features recently 
have been found to increase 
the risk of relapse. Both the 
American and European drug 
authorities require histology 
as an endpoint in clinical 
trials. The features that best predict relapse in patients with quiescent disease are increased neutrophils 
in lamina propria, basal plasmacytosis and mucin depletion (172-174).  
As with the previous modalities there is no definition of histologic remission, nor is there a consensus 
of which scoring indices to use. Consequently, there are different remission definitions across the 
different scoring indices. The three most applied scoring indices are Geboes Score (GS), Robarts 
Histopathological Index (RHI) and Nancy Index (NI), and previous papers have reported remission 
cut-offs that span <2.1-3.1, <3-5 and 0-1, respectively (175-178). Despite having several different cut-
offs histology has proved to be able to detect clinically relevant inflammation and predict relapse 
independently (179-182). 










0: Normal vascular pattern 
with arborisation of 
capillaries clearly defined 
1: Blurring or patchy loss of 
capillary margins 
Bleeding 0: None  
1: Mucosa  




1: Some spots or streaks of 
coagulated blood on the 
surface of the mucosa.  
2: Some free liquid blood in 
the lumen 
3: Frank blood in the lumen 
ahead of endoscope or visible 








3: Deep ulcer 
1: Tiny < 5 mm defects in the 
mucosa, of white or yellow 
colour with a flat edge. 
2: Larger > 5 mm defect in 
the mucosa, which are 
discrete fibrin-covered ulcers 
in comparison with erosions 
but remain superficial. 
3: Deeper excavated defects 
in the mucosa, with a slightly 
raised edge. 
Table 3 The Ulcerative Colitis Endoscopic Index of Severity*. 




Drawbacks with histology are the slight increased risk of perforation under the procedure and the 
subjective nature of the image interpretations. RHI and NI are the only validated histological scoring 
indices and they have acceptable reliability and responsiveness (183). Interestingly, neither of them 
evaluates basal plasmacytosis or mucin depletions explicitly.  
1.2.1.4 Serological factors 
Both endoscopy and histology suffer from the same drawbacks, namely the cost and the risk of 
performing an endoscopy. Therefore, it is enticing to have a systemic marker, detectable in bloodwork 
for evaluation of remission. The only serological factor commonly used in disease evaluation is C-
reactive protein (CRP), but it not recommended as a criterion for remission. This is because of the low 
sensitivity to low grade inflammation in the colon (184, 185). At diagnosis and in severe cases CRP 
has proved to be useful in predicting outcome and response to medication (186-188).  
With the advance of more sophisticated tools for analysing blood, composite panels with many 
different markers have emerged. Planell et al applied microarrays to identify gene transcripts which 
can divide patients into a high- and low-risk group at diagnosis (189). Biasci et al. applied the same 
method to develop a panel which correlated well with endoscopy and was sensitive to changes, thus 
potentially being useful in the clinical evaluation of UC (190). Buorgonje et al. applied enzyme-linked 
immunosorbent assays (ELISA) to identify a combination panel consisting of serum amyloid A 
(SAA), IL-6, IL-8, and Eotaxin-1 which reliably can predict endoscopic disease activity in IBD (191). 
Kalla et al. developed an oligo-protein panel which identified patients with increased risk of treatment 
escalation (192). 
1.2.1.5 Faecal factors 
As with serum markers, faecal markers are more readily available than endoscopy and can be 
performed to a fraction of the cost. Unlike serum markers, faecal markers have the added benefit of 
representing the GI-tract rather than being systemic, which gives a more direct insight to the situation 
in the lumen of the GI-tract. Faecal calprotectin (FC) is the most applied faecal marker. It is a calcium 
binding protein found in neutrophils. Inflammation of the colon elevates calprotectin and this is a good 
marker for distinguishing between inflammatory conditions and functional diseases (193). 
Unfortunately, it does not have the same characteristics when discriminating between active and 
remission stages of UC (194). It has been proposed as a surrogate marker for mucosal healing with 
acceptable characteristics regarding sensitivity and specificity (195, 196). There are conflicting results 
regarding calprotectin’s’ ability to predict relapse. Theede et al. found that FC with a cut-off 
>321mg/kg is predictive of relapse, whereas Zhulina et al. report that a doubling of FC levels between 
two tests taken 3 months apart is predictive of relapse (197, 198). A meta-analysis performed by Li et 
al. found significant heterogeneity in the cut-off value for FC but suggest that consecutive tests could 
be beneficial in predicting relapse. The lack of a validated testing regime with cut-off values prevents 
FC from being a part of the UC remission definition. In addition, FC is not disease specific and the 
amount can vary greatly depending on the passage time of the stool (199).  
Other suggested faecal tests are lactoferrin and Faecal immunochemical test (FIT), but they are not as 




1.2.1.6 Transcriptional factors  
With the technology to analyse gene transcripts becoming readily available, one can delve even deeper 
into the core mechanics of inflammation. Since endoscopy is routinely performed on UC patients. it is 
possible to get samples from the core of the disease both in quiescent and active disease. Therefore, 
there is a potential for transcript biomarkers to be disease specific and to have excellent test qualities. 
TNF transcript has shown promising results as it correlates well with the grade of inflammation, and 
normalization predicts long term remission in UC patients (201, 202). IL33 is another cytokine 
showing promising results as a biomarker for remission (111).  
Due to the complexity of cell signalling and biomechanics it is unlikely for one transcript to solely 
predict remission or relapse. Planell et al. performed a microarray analysis on non-IBD, remission UC 
and active UC, and discovered several upregulated genes in UC compared to non-IBD and where a 
significant number of genes were differently regulated in UC remission (203). These genes were at 
large related to epithelial cell proliferation, resistance to apoptosis, stress and wound healing. Fenton 
et al. found a different transcript profile by investigating mucosal biopsies with next-generation 
sequencing (NGS) (204). They found, as Planell et al., that restoration and improvement in the 
epithelial and mucus layers define the remission state. In addition, they found downregulation of Toll-
like receptors transcripts which suggests a more inert immune response. They imply that this could be 
a result of medication. Another study found that transcripts related to expression of IL17A/F and IL21 
are predictive of relapse (205). 
Transcripts have the benefit of being a clear window into the cells and mechanisms of UC pathology. 
Although, in a pathophysiological investigation the information gathered form transcripts are limited 
by the post-translational processes, which changes the resulting protein. Therefore, any transcriptional 
finding should be validated on a protein level, by histochemistry or proteomics.  
1.3 Summary of introduction 
UC is a chronic disease of the colon. The pathogenesis is currently not known, but the disease is 
believed to have a multifactorial cause. There is no cure with except of removing the colon, but recent 
advancement in treatment algorithms and medication have lowered the colectomy rates and reduced 
the risk for colon cancer. Despite these improvements a large part of the UC population is still 
troubled by relapses. The current management suffers from lack of coherence in terms, definitions and 
modalities of evaluation, making it difficult for the clinician to provide the best care for the patient. 
There are factors across several modalities that can predict beneficial outcome for UC patients. 
Symptoms, endoscopic evaluation and faecal calprotectin are already included in clinical practice to a 
certain extent. Factors within other modalities like histology and transcripts lack sufficient evidence to 
be included. To address this, the remission state must be thoroughly described with the modalities in 
question.  
The purpose of this thesis was to lay a foundation for a more coherent practice by describing some of 
the different aspects of remission. These aspects were the transcriptional remission profile, the 
reliability of histologic evaluation of UC remission samples and, ultimately, to evaluate if any of these 




2 Aim of the thesis. 
2.1 Hypothesis 
To be able to provide precision medicine for UC patients, a clear definition of remission is needed. 
The defined remission state should be a state yielding a high likelihood of long-term remission. 
Remission could be described by different modalities, the most interesting being transcriptional, 
histology and endoscopy. The working hypothesis was that a thorough description of the UC 
remission state across several modalities might give the patients a better prognosis by increased 
precision of their treatment. 
2.2 Aim 
Aim 1: To characterize mucosal transcript of UC patients in clinical remission 
Aim 2: Evaluate the reliability of the three most applied histologic indices in patient with endoscopic 
defined remission. 







3 Material and methods 
3.1  Population 
All the three papers included in this thesis have been part of the Advanced Study of Inflammatory 
Bowel disease (ASIB) prospective study at the University Hospital of Northern Norway, Tromsø. 
Every study participant gave a written, informed consent with the possibility to withdraw participation 
after inclusion. The studies and storage of biological material were approved of by the Regional 
Committees for Medical and Health Research Ethics, division North (REK Nord ID:2012/1349) and 
the biobank was approved by the Norwegian Institute of Public Health (04/01690 HOD).  
The selected participants presented in Table 4 were previously diagnosed with UC according to 
diagnostic guidelines (156). Sample collection was performed at routine endoscopy for patients in 
remission from August 2013 to April 2016. Inclusion criteria were patients aged between 18 and 80 
with clinical and endoscopic remission defined as Mayo Clinical Score/Ulcerative Colitis Clinical 
Score (UCCS) of 0 or 1 and Mayo Endoscopic Score (MES) of 0 or 1. Patients with a total Mayo score 
above 1 or rectal bleeding were not included. IBD medication was neither an inclusion or nor an 
exclusion criterion. Baseline information was collected from a questionnaire answered at inclusion or 
from a review of the patient’s journal. 
Table 4 Overview of study design. The 41 UC remission participants in paper 2 and 3 were the same 
and they were drawn from the original 48 participants in paper 1. 
 Included Study type 
Paper 1 48 UC 
24 Normal controls  
Case-Control observation 
Paper 2  41 UC remission Cross sectional observation 





A control group of 24 non-IBD participants screened with colonoscopy for colorectal cancer or mild 
gastrointestinal symptoms were included. Criteria for non-IBD controls were no diarrhoea or other 
irritable bowel symptoms, as well as a completely normal endoscopy, with no polyps in sigmoid and 
no hyperplastic polyps in rectum lager than 5mm. Only non-IBD participants with Geboes score of 0 
were included.  
3.2 Sample analysis 
All patients went through endoscopy with biopsy collection for quantitative polymerase chain reaction 




3.2.1 Quantitative Polymerase Chain Reaction 
qPCR is a method that can detect, classify and monitor DNA and RNA targets. It is a relatively fast 
and cheap way to accurately quantify genes and gene expression, and it has a wide range of 
translational applications (for a review see (206)). When analysing gene expression, RNA is of interest 
and in cells it exits in different subtypes such as ribosomal RNA (rRNA), transfer RNA (tRNA) and 
messenger RNA (mRNA). mRNA is the essential bridge between the genetical code (DNA) and the 
resulting protein and it is the target when preforming gene expression analysis. qPCR can detect 
mRNA transcripts in any biological sample if the transcript is known. However, there are both 
biological and technical limitations to the method which may challenge the accuracy of qPCR. The 
following sections presents the method in general and discuss its limitation. 
Method 
The analysis starts with extracting totalRNA (all types of RNA) form the biological sample and 
storing it. After the sample is extracted the RNA quality deteriorates rapidly, therefore the sample 
must be stored at -70℃ to maintain the integrity. Reverse transcription is the second step of the 
process and here the mRNA is copied in a proportionate amount to complementary DNA (cDNA). 
This product is the template used in the polymerase chain reaction (PCR) in step three. The PCR takes 
place in a thermal cycler that duplicate the template of interest and measure the amount. The thermal 
cycler works by heating and cooling the enzymatic reaction between DNA template and the 
polymerase in cycles. Before the cycle starts, there is an initial heating step where the solution is 
heated up to 95℃ for 2 minutes to separate secondary structures and activate Taq DNA polymerase. 
Thereafter, the cycles start by cooling the solution to 60℃ to allow for the primers and probe to anneal 
and elongate the primers with a strand complementary to the template. Next, the solution is heated to 
95℃ in order to denature the newly synthetized double stranded DNA (dsDNA) into single stranded 
DNA (ssDNA). The solution then cools again, and the cycle is repeated 40 times and, if there are 
sufficient reagents, the amount of template is doubled after each cycle. The detection is done by 
registration of a fluorescent signal which is released in the presence of a specific gene sequence or 
dsDNA depending on method. If the gene of interest (GOI) is present it will for each cycle release a 
stronger signal which is proportional to the amount of template present (207). The cycle threshold (CT) 
is the cycle for when the intensity of fluorescence signal reaches a set value. The more GOI in the 
sample the lower the CT will be, since the threshold is reached with fewer cycles.  
Figure 1 Procedural flow of a qPCR experiment. 
 
There are different methods for detection of targets. Our laboratory applied both hydrolysis probe and 
SYBR-green. Hydrolysis probe is a technology where the probe sits between two primers and is 
conjugated with a reporter dye on the 5’end and quencher dye on the 3’end. The probe anneals with 
the targeted gene sequence on template DNA and the polymerase arrives to duplicate the target. The 
polymerase then dismantles the probe and thus releases the dye on the 5’end and distance it from the 
effect of the quencher. This removal allows the dye to release the fluorescence. The SYBR-green 




fluoresces when bound. After each elongation in the PCR cycle SYBR-green attaches itself to the 
minor grove of the dsDNA and releases itself when the product denatured. The most important 
difference between the two methods is that SYBR green is cheaper and faster as it does not require a 
custom-made probe design. However, SYBR-green is less specific than the hydrolysis probe as it will 
bind to any dsDNA in the experiment, including misaligned primers and undesirable genomic DNA 
(gDNA). In addition, there is always background noise with SYBR-green analysis, therefore, the 
fluorescence signal will first be detectable when there are enough amplicons which releases the 
fluorescence. Despite these problems, studies have found that a well-designed and optimized SYBR-
green assays can perform at the levels of the hydrolysis probe (208).  
Figure 2. SYBR-green vs TaqMan. Illustrated difference between SYBR-green and hydrolysis probe 
(TaqMan). Printed with permission from SMOBIO Technology, Inc. Retrieved from 
https://www.smobio.com/faq-real-time-pcr “Real-time PCR Related Questions”, 19.02.2021 
 
Primers and probes 
The internal validity is dependent on an optimal primer and probe design (assays). Assays can be 
designed in house through different software. It can also be bought from manufactures or be copied 
from previously published and validated assays. The hydrolysis probes were designed in-house with 
Beacon Designer v8 (PREMIER Biosoft International, Palo Alto, USA). To ensure specificity for 
mRNA, all probes spanned exon splicing sites. In addition, all primers and probes were run through 
Basic Local Alignment Search Tool (BLAST) to ensure specificity for the mRNA sequence in 
question (209). The efficiencies of all assays were measured by analysis of a dilution series standard 
curve made from cDNA from an actual biopsy. The SYBR green assays were ordered from Qiagen 
(Qiagen N.V, Venlo, Netherlands) and, consequently, the qualities of the SYBR Green assays were 
assured by Qiagen.  
RNA quality  
The quality of the RNA is paramount for accurate measurement of GOI. Sampling, storage, and 




were immersed in RNAlater from Qiagen immediately after extraction. RNAlater is a solution that 
stabilize and protect cellular RNA in situ in unfrozen specimens. It postpones the need for freezing the 
samples which can be kept up to 1 week in room temperature (25oC). RNA preservation was evaluated 
at our laboratory in 2006, and it was concluded that our handling of the samples exhibited minimal 
loss of RNA quality (210). RNA integrity number (RIN) is a scoring system that has been developed 
to report RNA quality. RIN over 5 indicates good quality and RIN over 8 is near to perfect total RNA 
(211). The average RIN value for a representable sample set from our population was 8.40 with a 
standard deviation of 1.67.  
Reverse transcription 
The conversion of mRNA to cDNA is a sensitive step in the qPCR process. It is important that the 
strategy and reaction conditions are the same in all experiments. To have an equal condition for all 
samples there must be an equal concentration of totalRNA in each reaction tube. Therefore, the 
totalRNA concentration and the calculated volume needs to be measured from each sample. Reverse 
transcriptions for the hydrolysis probe assays were performed with QuantiNova Reverse Transcription 
Kit, while, the SYBR-green assays utilized RT2 First strand Kit. Both kits were performed according 
to manufacturer’s instructions.   
Normalization 
The qPCR method is limited by the uncertainty whether an observed difference is a consequence of 
true difference or error introduced by handling and preparation. When measuring genes, it is most 
common to measure it in relative amount to a known reference gene, so-called endogenous reference 
gene (RG) or housekeeping gene. This is necessary because it corrects for errors in the sample, 
introduced through handling, preparation and measuring. This correction is called normalization. The 
assumption is that a reference gene is stably expressed between samples and variations seen in this 
gene reflects technical imperfections only. The ideal reference gene is independent of any disease, 
condition, or external stimulus. Thus, candidate genes are often involved in basic and universal 
“housekeeping” cellular functions (212). However, there are studies suggesting that there are 
considerable variations even in these genes (213). Reference genes should therefore be validated for 
each experiment. In the present study actin-beta (ACTB) was applied for the hydrolysis probe 
experiments. ACTB had been previously used in our lab and had shown stable results with experiments 
with UC. For the SYBR-green experiments the geometric mean between HPRT1 and RPLP0 was 
applied (214). These later reference genes were found to have good stability value in an in-house 
validation study preformed with the normFinder method (215). The use of only ACTB in the 
hydrolysis probe experiment was a weakness and is not recommended by the Minimum Information 
for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines. (216). 
Reproducibility 
As mentioned, all samples were run in duplicates, and if the difference was larger than 0.5 CT values 
the sample was re-measured. Alle PCR runs had both positive and negative controls to check for 
contaminations. Interplate calibrator (IC) was the same as positive control and all plates were adjusted 
to the geometric mean of the ICs. Samples giving a measurable signal after 40 cycles were excluded as 
it implied a minute number of starting templates this implies, and a subsequent inherent risk of 




Relative quantification and the comparative-method 
CT is the cycle number for when the fluorescence signal reaches an arbitrary threshold. The threshold 
is placed in the exponential phase of the amplification, and the same threshold must be used for all 
experiments. The numerical value of CT is inversely related to the amount of amplicons in the reaction 
(217). There are primarily two ways to report qPCR data, by absolute quantification or by relative 
quantification. The absolute quantification allows for precise determination of copy per sample. It 
requires the construction of an absolute standard curve for each individual amplicon (218). In relative 
quantification the data is presented relative to another gene. The method is called comparative CT or 2-
ΔΔCT-method. The method assumes that the efficiency of the PCR is close to one and that the efficiency 
of the GOI is similar to the reference gene (217, 219). The disadvantage of the absolute quantification 
method is the increased effort to make a standard curve. In most experiments it is sufficient to report a 
genes fold change rather than exact numbers. In papers 1 and 3 the comparative CT-method was 
applied. 
3.2.2 Histology 
Histopathological samples were collected during the ASIB-study. In total 41 UC participants had 
samples of adequate quality to be included. The samples were evaluated by three pathologists, two 
general pathologists and one expert gastrointestinal (GI) pathologist. Two of the pathologists rated the 
samples on a white light microscopy, while the third evaluated them digitally with scanned slides. To 
investigate the difference between white light microscopy and digitally scanned slides, one pathologist 
assessed all the samples a second time on the other modality after an interval of 3 months. All samples 
were evaluated with three different histological indices (Robarts Histopathological Index (RHI), 
Geboes Score (GS) and Nancy Index (NI)). All pathologists had a scoring protocol consisting of the 
three original publications of the indices, together with one aid article for Nancy Index and a miniature 
scoring atlas produced by the developers of RHI.  
3.3 Statistical methods 
In paper 1 the difference in gene expression between the groups was investigated using Two-way 
ANCOVA models. Assumption of normality was checked with histograms, Q-Q plots and the 
Shapiro-Wilks test. Genes not displaying a normal distribution were evaluated with appropriate non-
parametric tests such as Mann-Whitney U-test. All tests were two-sided and p-values below 0.05 were 
considered statistically significant. Benjamini-Hochberg correction for multiple comparisons was 
calculated and presented. The hydrolysis probe dataset was larger and investigated the difference 
between two groups (UC remission and non-IBD). The final model could adjust for age, gender, MES 
and GS. The SYBR-green dataset was smaller and investigated differences between three groups (non-
IBD, UC remission and UC active). Therefore, this model could be adjusted for age and gender only.  
The assessment of the reliability of the histologic evaluation in paper 2, was performed with two 
different methods. First by calculation of the Intraclass Correlation Coefficient (ICC) and secondly by 
a visual representation with Bland-Altman plots. The inter-rater ICC was calculated with two-way 
random, average score ICC for consistency (C,3), while the intra-rater ICC was calculated as a single 
score ICC for absolute agreement (A,1). The Bland-Altman plot is usually performed between two 
variables, but Jones et al. developed a method to visualize agreement between multiple raters (220). In 




facilitate comparison between the scores, all scores were standardized by dividing them on their 
theoretical max. Because of skewness in the raw data, all scores were transformed by square root.  
Fleiss' kappa was applied on agreement evaluation between categorical variables and evaluated 
according to the definitions of Landis et al. (221). Systematic difference in rating between the raters 
was investigated with Kruskal-Wallis rank sum test. If significant, a sub-analysis with Wilcoxon rank 
sum test was performed to identify how the graders differed. Relationships between two dichotomous 
variables was assessed with Fisher exact test. 
Variable selection was a challenge in paper 3 as there was a high number of covariates and a low 
number of cases. In total there were 42 covariates, 41 cases and 14 events. There are several ways of 
dealing with this, such as multiple testing and adjusted p-values, stepwise regression, or penalized 
regression. In multiple testing, all variables are run through a univariate regression analysis and the 
variables are selected according to a p-value adjusted for multiple comparison. The problem with this 
approach is that it does not account for effect size. Stepwise regression is challenged both by a high 
number of covariates compared to cases and multi-collinearity (222). Penalized regression handles 
these issues better. In penalized regression, a penalizing factor is added to the regression model to 
adjust for having too many variables. The least absolute shrinkage and selection operator (LASSO) 
method has the effect of reducing the coefficients of variables with minor contribution to the model to 
almost zero. This qualifies it to make a subset selection of variables. Finding the optimal penalizing 
factor is often done through cross validation, and the glmnet package for R can calculate LASSO 
regression with cross validation. Due to the “random” partition of the data set for the cross validation 
there is an element of non-random “randomness”. To account for this, the LASSO regression and 
cross validation were performed 10 000 times with different seeds, and the number of covariates with 
non-zero coefficients were counted. This method was proposed by Vinvand in a master thesis as a way 





4 Summary of results 
 
4.1 Paper 1 - Mucosal transcript characterization of Ulcerative 
colitis in clinical remission 
“The mucosa of UC in clinical remission differs from normal mucosa, suggesting a dysregulation 
of inflammatory and wound healing mechanisms” 
72 participants (44 UC remission, 4 UC active and 24 non-IBD) donated biological material for 
transcriptional analysis. The aim was to compare known inflammatory and healing mediators in the 
mucosa of UC in clinical remission with normal controls.  
Among the 51 mucosal transcripts examined, ten were significantly regulated between UC remission 
and non-IBD., eight were upregulated (IL1B, IL33, TNF, TRAF1, CLDN2, STAT1, STAT3 and 
IL13Ra2) and two were downregulated (TBX21 and TGFB1). Between UC active and non-IBD nine 
transcripts were significantly upregulated (ADAM17, CASP8, TRAF1, CLDN2, DEFB1, IL13RA2, 
STAT1, STAT3 and TFF3) and one downregulated (CHUK). IL1B differed significantly in expression 
between genders, where males had a higher expression than females. All comparisons were adjusted 
for age and gender 
Mayo Endoscopic Score (MES) of 1 differed from 0 on a transcript level, as several master 
transcription factors for T-cell development (TBX21, GATA3, RORC, SPI1 and FORXP3) were 
upregulated in MES 1. In addition, IL6, IL10, IL33, ST2, TLR4 and TGFB1 were upregulated in MES 





4.2 Paper 2 - Real life evaluation of histologic scores for 
Ulcerative Colitis in remission 
“A substantial amount of UC patients in clinical and endoscopic remission display inflammation 
on a histological level, but the ability to classify these patients accurately and consistently could 
be improved.” 
Mucosal biopsies from 41 UC patients in clinical remission were collected for histologic evaluation by 
three pathologists according to three different indices.  
The Inter Class Correlation (ICC) coefficient for Geboes Score (GS), Robarts Histopathological Index 
(RHI) and Nancy Index (NI) were 0.85, 0.73 and 0.70, respectively, and the limits of agreement were 
±6.1, ±4.0 and ±1.4. One pathologist rated systematically higher than the other two on all three 
indices. Neither colon location nor medication seemed to have any association with the histological 
scores. Categorical agreement on the remission state was assessed with Kappa Fleiss and showed a 
fair to moderate agreement between the pathologists.  
Mayo endoscopic subgrade and Ulcerative Colitis clinical score did not show association with any of 
the histological scores. Despite clinical and endoscopic remission, 7-35% of the patients displayed 





4.3 Paper 3 - IFNG:IL33 ratio predict relapse in UC remission 
patients 
“A ratio between IFNG and IL33 is predictive of relapse and could be a potential new 
biomarker for relapse in UC remission patient” 
42 variables were gathered form 41 participants in clinical and endoscopic remission of UC in order to 
investigate their predictive abilities of relapse.  
Among the 41 participants, 14 experienced relapses during the follow-up. The median follow-up time 
was 6.5 months (IQR 6.6) for those who experienced relapse and 12 months (IQR 11) for the non-
relapsers. Of 42 variables eight showed non-zero coefficients in a LASSO regression analysis. Of 
these eight the best performing factor was a ratio between IFNG and IL33. The univariate cox 
regression analysis showed 5.3 times (95%Cl = 1.8-15.4) higher risk of relapse in a low IFNG:IL33 
ratio group than in a high group. The IFNG:IL33 ratio performed better than both UCCS and MES in 
predicting relapse. Histologic evaluation could not predict relapse. Immunostaining showed IL33 
presence in endothelial cells and mononuclear cells in the lamina propria. No difference in IL33 






5.1 Methodological considerations 
5.1.1 Study design  
An overview of the different study designs is presented in table 4. The case-control design in paper 1 
restricted the possibilities of concluding the direction of the found association. Paper 2 is an 
observational study of the reliability of histologic evaluation. It does not address whether a pathologist 
evaluated true or false, but rather how similar three pathologists rated UC remission biopsies. The 
design of paper 3 made it possible to evaluate the predictive impact of the variables evaluated. Their 
predictive capabilities, however, need to be validated in another independent data set. 
5.1.2 Internal validity 
Internal validity is defined as the extent to which the observed results represent the truth in the studied 
population and not methodological errors. The errors may be divided into selection bias, information 
bias and confounders. In the following chapters the methodological challenges of the main analytical 
methods used in this thesis will be debated. The methods applied were quantitative polymerase chain 
reaction (qPCR) and histology.  
5.1.2.1 Selection bias 
Selection bias may arise when the subjects included in the study differ from the source of the 
population. In paper 1 there could be a potential for selection bias due to the selection of non-IBD 
controls. The patients were referred due to GI-symptoms or suspicion of GI-cancer, which resulted in 
an age difference between the case and control group. The mean age for the UC group was 40.5 (sd: 
12.9) years, compared to 54.6 (sd:18.6) years for the non-IBD, which was unfortunate but difficult to 
avoid. To adjust the for the age difference, age ought to be included in a multivariate analysis. Ideally, 
the controls should have been selected from a healthy population without complaints, but this was 
difficult due to the nature of the sample collection procedure. By only including non-IBD patients 
having no irritable bowel syndrome (IBS) symptoms, no polyps in rectum lager than 5 mm and 0 on 
both the MES and the Geboes histological scores, the control group approximated a healthy 
background population as much as possible.  
Patients declining to enter the study might also result in selection bias as they could be systematically 
different from those who were included. In this study the overwhelming majority accepted 
participation and the effect size of this bias would be minute.  
5.1.2.2 Information bias 
Information bias is a systematic difference from the truth that arises at the collection, recall, recording, 
and handling of information in a study, including how missing data is dealt with (224). Information 
bias will be discussed in relation to qPCR, histology, assessment of disease activity and endpoint 
registry.  
Limitation of transcript analysis 
The qPCR analysis provides a snapshot of the amount of mRNA in that exact location at that time. Wu 
et al. found that a single pinch biopsy from the colon was highly reflective of that segment (225). 




determining whether the templates result in a functional protein (226). Ultimately, the proteins are the 
direct executors of life processes, and any qPCR experiment should be validated on a protein level. 
This can be done by immunohistochemistry or mass spectrometry. These methods are either more 
time-consuming or more expensive, and qPCR serves well in a discovery phase as a hypothesis 
generator. The key assumption is that no proteins exist without a previous mRNA template and, to a 
certain degree, that there is a correlation between the amounts of transcript and protein (227, 228).  
A limitation of SYBR-green assays is the sensitivity for genomic DNA (gDNA). As SYBR-green 
binds unspecific to double stranded DNA, any failure in completely removing gDNA or by 
contamination could produce an erroneous result. The length of a standard amplicon should be 50-200 
base pairs (bp) while gDNA usually is much longer due to introns (229). A longer length will allow 
many SYBR-green fluorophore to bind and even minor amounts of gDNA would produce a strong 
signal. Proper handling limited the likelihood of this to happen and post-PCR melting point analysis 
allows detection of any false signals 
Gene selection 
The genes of interest (GOI) were selected based on literature and previous assays present in our lab. 
They do not give a full picture of all the different transcribed genes in remission but function rather as 
a targeted investigation based on previous knowledge. The selected genes were found to be important 
in animal models but unproven in human studies or genes found to be central in active UC but 
uncertain in remission. Some genes were representatives of the cell population and gave an indication 
of cell composition in the mucosa.  
Clinical and endoscopic factors  
Remission was defined as Mayo clinical score/UCCS of 0 or 1, with an endoscopic subscore of 0 or 1. 
No points were allowed on rectal bleeding and the total Mayo score could not be larger than 1. This is 
widely applied definition (134, 156).   
The factors MES and UCCS in paper 1 and 3 were partly subjective interpretations and consequently 
there was a risk for misclassification. The main purpose of paper 2 was to address problems with 
subjective evaluation, but with focus on histopathology. All three papers relied on patients classified 
as remission patients. As this was done by two partly subjective scores, misclassification of case and 
controls could be a possibility. In paper 1 such a misclassification could have resulted in some of the 
remission patients ending up the active group and vice versa. In order to have an effect on the results, 
the misclassification had to be skewed in one direction. For example, the physicians should have 
systematically underestimated or overestimated the patient’s symptoms. There was, however, no 
indication that this was the case. The differences found between MES 0 and 1 could have been a result 
of different operators making the assessment, as the untrained inter-rater agreement is moderate (230). 
In paper 2 we acknowledged the potential information bias in evaluation of histologic samples. 
Evaluating the intra class correlation and kappa Fleiss gave an understanding of the extent of this issue 
before investigating if histology might predict relapse in paper 3.  
Relapse 
In paper 3 the factors from papers 1 and 2 were used to investigate if they could predict relapse in this 
sample population. Relapse was defined as any increase in medication and contact with health care 




without contacting the health care provider. This would have resulted in fewer relapses in the data set 
than the true value. The same result could be true if a patient moved to another hospital during the 
follow up time. The relapse rate, however, was 34% with a median follow-up time of 8 months which 
was in line with previous reports (146).  
Confounding 
A confounding variable is a third unmeasured variable that influences both the independent and the 
dependent variable resulting in an erroneous understanding of the association between the two 
measured variables. Age, sex, and disease duration were variables likely to influence the gene 
expression in the colon and should be included in the analyses. In paper 1 the hydrolysis probe results 
were analysed with a model that adjusted for sex, age, MES and GS. Unfortunately, due to a lack of 
power the SYBR-green assay results could only be adjusted for age and sex. In paper 3 the lack of 
power prevented any adjusting for potential confounding variables. This proved to not be detrimental 
as all variables were run through the LASSO regression and only age and disease duration were 
potentially important. Regardless, with such small coefficients the real impact would still have been 
negligible. Furthermore, the associations reported in paper 3 need to be validated in an independent 
larger dataset where the potential confounding factors could be more thoroughly investigated. 
In paper 2 the agreement between three pathologists evaluating UC remission biopsies were assessed. 
A flaw in the study design was that the pathologists were blinded to the biopsy locations. It is an 
established fact that there is a higher number of eosinophils in the proximal colon than in the distal 
segments (231). Therefore, an assessment of “normal eosinophils” was dependent on location. Also, 
one pathologist evaluated the slides digitally after scanning, which lowered the ability to detect the red 
granules, characteristic for eosinophils. These two confounders contribute to the artificially high 
disagreement between the pathologists regarding to eosinophils.  
5.1.3 External validity 
External validity refers to how well a study’s outcome relates to the general population in focus. 
Internal and external validities are often in opposition to each other, where one must make sacrifice on 
one end to improve the other. The inclusion criteria did not discriminate on medication and thereby 
improving the external validity as a wider spectrum of treatment regimes were represented in the 
material. Also, including patients in different clinical situations (treatment stops, 6-months follow-ups 
or routine cancer screenings) increased the external validity in paper 1 and 3. In paper 2 the external 
validity was related to the pathologists rather than to the UC patients. As paper 2 included both one 
GI-specialized and two general pathologists the results were more representative for pathologists in 
general, compared to if only GI-specialists had been used. Nevertheless, even within the general 
pathologist population there is a variation in the number of evaluated IBD samples which probably 
will affect the application of the histologic scoring indices. Therefore, generalization of the results in 
paper 2 to other hospitals should be done with caution.   
5.2 Main results 
In-depth discussion of the main results can be found in the respective papers 1-3. In the following 
sections the potential and limitation of histology in the context of UC categorization will be discussed. 
This will be followed up by a discussion about remission classification with focus on immune 




5.2.1 Histologic evaluation of remission  
Could histology be the next target in the treatment of UC? Histology is an established tool in the 
diagnosis of UC with characteristic goblet cell depletion and crypt abscess features, but it has not been 
proven with respect to treatment decision and routine evaluation. In recent years there has been an 
increased focus on histology as treatment target and criteria for remission. There have been two large 
systematic reviews regarding this topic during the last 10 years, one by Bryant et al. and one by Battat 
et al (179, 232). Bryant suggests in 2014 that histology can be predictive of relapse in UC, but that it 
suffers from lack of standardization and validation as too many different indices and cut-offs are used. 
Battat et al. harmonize this notion in their paper reviewing histology’s role in clinical trials. In a newly 
published paper, The European Crohn's and Colitis Organisation (ECCO) addresses the lack of 
standardization by recommending the use of either RHI or NI, and recommending specific cut-off for 
remission (RHI<4 and NI=0) (233). Although a protocol for biopsy collection in the diagnosis of UC 
is recommended, no recommendations are offered for histologic sample collection during routine 
investigation.  
In paper 2 the agreement between three pathologists was investigated. Two of them were general 
pathologists while the third was a GI-specialized pathologist. The aim was to evaluate how coherent 
these pathologists rated remission biopsies, and to investigate if the agreement differed between 
different histologic indices in order to discover potential limitations of using histology as a treatment 
target. The three most applied histologic indices (GS; RHI and NI) were investigated to determine 
which was the most preferable. The results showed that all three indices had similar agreement, but 
there was a clear difference between the pathologists. The GI specialized pathologist rated consistently 
higher in all the indices. Interestingly, there was no difference in the inter-quartile range suggesting 
that the pathologists rated consistently with their subjective understanding of the indices. It also 
indicated that sub-specialization might affect accuracy but not necessarily the precision. The 
agreement for categorization of the patients into remission or active groups was only fair to moderate 
for all indices. In a clearer term, the pathologists agreed on whether a patient was in remission or had 
active disease in 51-89% of the cases, dependent of score and cut-off.  
Several different cut-offs have been used in previous reports, and agreements have differed in either 
extreme end of the indices. The present study investigated if there was an agreement difference 
between strict (GS <2A.1, RHI <4 and NI = 0 ) and relaxed (GS <3.1, RHI <5, NI <2) cut-offs (172, 
173, 181, 234-240). The cut-offs were based on previous literature and the results showed that the 
strict cut-offs had a lower percentage of agreement.  
The results showed lower rater agreement than the developers of the scores have reported (176, 177). 
This could be due to lack of training or experience of our pathologists. In both the original RHI and NI 
validation papers the evaluating pathologists were given extensive training (176, 177), while our 
pathologists only received a scoring aid protocol (se Method chapter). It could be questioned whether 
a protocol was sufficient to ensure proper rating, but arguably this setting was closer to a real-world 
setting where general pathologists will be asked by clinicians to use disease specific scores without 
receiving specific training. In a similar study Villanacci et al. investigated the real-world usefulness of 
histology in UC using two differently experienced pathologists (241). They were not given specialized 
training to improve coherent ratings, but they were both GI-pathologists who were familiar with the 




pathologists in scientific studies may be reasonable but it limits the generalization of their results since 
sub-specialization outside tertiary care centres is rare.  
The limit of agreement (LOA) gives the interval of error for a repeated measurement. The error 
includes both systematic error and random error. The results from paper 2 suggested that the limits of 
agreement were ±6.1, ±1.4 and ±4.0 for GS, NI and RHI respectively. For easier comparison, the 
scores were standardized which gave the following values: 0.53, 0.59 and 0.35. RHI had slightly better 
LOA than the other two, but in absolute numbers the interval was substantial. This indicated that 
histology at this level was rather insensitive to changes as a large portion of the difference observed 
could be attributed to error rather than actual difference. This was unfortunate as the histologic 
evaluation of remission patients is an exercise in observing minor changes and the majority of patients 
will have few features of inflammation.  
Jairath et al. found good correlation and response between histology and other clinical parameters such 
as the Total Mayo score, while Lobatón et al. found poor correlation between GS and MES (180, 183). 
The results from paper 2 did not show any association between UCCS, MES and any of the histologic 
indices. This discrepancy in results might be attributed to inclusion differences. Jairath et al. used data 
from the Touchstone clinical trial which included participants representing the whole range of the 
histologic scores. Conversely, in paper 2 only patients in remission according to the latest guidelines 
were included. These strict inclusion criteria and long remission times for many of the participants 
reduced the number of samples with residual histologic inflammation. This revealed the true 
usefulness of histology since there were few participants in the higher end of the indices with obvious 
signs of inflammation. The strict selection might be interpreted as a “stress test” of the histological 
indices.  
The substantial inter-rater variation limited the applicability of the histologic evaluation of UC patients 
in remission. A way to amend this could be by adopting a central reader approach. Despite performing 
the rating in two different manners, with white light microscopy and digitally on a screen with scanned 
slides, the intra-rater value was good to excellent, with exception for the eosinophile feature in GS. 
This indicated that little information was lost due to scanning and digitalizing the samples and it 
would be beneficial to have a specialized central reader evaluating the samples digitally. This could 
result in more coherent scoring, lower LOA and improved usefulness as there is likely to be improved 
resolution in the lower ends of the scores. 
In conclusion, the recommendation of histology as a requirement for remission is still questionable, 
especially outside centers with sub-specialized GI-pathologists. Rather than having histology as a hard 
treatment target it would be more appropriately used as a soft aid in clinical decision.  
5.2.2 Immunological remission profile  
Gene expression is the foundation for all biological function in our organisms. Consequently, 
investigating the mucosal gene expression in UC may potentially reveal the crux of the disease. Much 
focus has been aimed at the gene expression of UC in the inflammatory state and less on the remission 
state, especially in human samples (225, 242, 243). The inherent problem with evaluating active UC is 
the distinction between what is core UC pathology and what is a result of inflammation in general. By 
investigating the UC remission mucosa, one could get information un-distorted by inflammation. This 




a difference between gene expression and functional protein. Therefore, any findings need to be 
validated on protein level.  
In paper 1, the immunological profile in the mucosa of UC patients in remission was investigated and 
compared to non-IBD controls and active UC. The transcripts were analysed either with hydrolysis 
probe or SYBR-Green. The aim was to characterize if, and how, the UC remission mucosa differed 
from the non-IBD in a search for knowledge about the core UC pathology. A total 51 genes were 
tested and 15 of these were differently expressed between the groups investigated. TNF, IL33, IL1B, 
TRAF1, CLDN2, IL13RA2, STAT1 and STAT3 were upregulated in UC remission compared to non-
IBD. TBX21 and TGFB1 were downregulated in the same comparison. ADAM17, CASP8, TRAF1, 
CLDN2, DEFB1, IL13RA2, STAT1, STAT3 and TFF3 were upregulated in active UC compared 
controls. CHUK was the sole transcript to be down regulated in active UC.  
TNF and IL1B are primarily pro-inflammatory, indicating that there is residual inflammatory 
signalling in UC remission mucosa on a transcriptional level independent of both endoscopic and 
histologic appearance. Interestingly, none of these genes correlated with histology (unpublished data). 
The role of IL33 in this setting was difficult to ascertain as it has dualistic properties. 
Immunohistochemistry did not reveal any difference in IL33 amount when comparing UC remission 
to non-IBD participants (unpublished data). The distribution of IL33 in the mucosa was also similar 
between the two groups, and it was mainly found in endothelial and mononuclear cells in the lamina 
propria. Gundersen et al. found IL33 to be located in the epithelial cells of active UC (111). The 
different localization of IL33 in our findings might suggest that it was exerting its anti-inflammatory 
properties.  
TGFB1 is an anti-inflammatory cytokine and in the results from paper 1 it was found to be 
downregulated in remission compared to non-IBD. TGFB1 is important for immune tolerance as an 
inducer of Tregs and in a quiescent state the tolerogenic processes should be increased, or on par, in 
comparison with non-IBD. TGFB1 is also found to be important in maintaining the intestinal barrier in 
animal models(120). The reduced expression could be a factor in the relapsing nature of UC as 
reduced TGFB1 could result in both weakened barrier and reduced tolerance function, which 
consequently would result in an active immune response. Other reports on TGFB1 in UC mucosa are 
conflicting (118, 244). 
IL1B, TGFB1 and IL13RA2 are implicated in wound healing and pro-fibrotic processes (97). TGFB1 
and IL1B regulate the production extracellular matrix in fibroblasts (245). Interestingly, IL1B and 
TGFB1 were inversely expressed which challenged the understanding. A study investigating fibrotic 
mediators in UC suggests that the balance of TGFB isoforms determines their functions (96). 
Unfortunately, the other isoforms were not investigated in this study. IL13RA2 was found to be 
upregulated in both UC active and UC remission. This might reflect either, the profibrotic properties 
or the proinflammatory properties IL13RA2 is found to have in animal models (246, 247). Information 
on IL13RA2 in human studies is scarce and it is difficult to accurately determine its function without 
further investigation. However, with increased expression of IL13RA2 and IL1B, it could point to 
ongoing wound healing/fibrotic processes.  
In paper 1, TRAF1 was found to be upregulated in remission mucosa. It is thought to function as a 




Interestingly, another upregulated gene in the remission group was CLDN2. CLDN2 is a protein which 
regulates tight-junctions in the epithelium, and an increase in the protein is associated to barrier 
dysfunction. CLDN2 is found to be upregulated in UC and to correlate with disease severity, but it is 
not previously described to be upregulated in remission mucosa (249, 250). The upregulated 
expression of CLDN2 in remission mucosa was supportive of the “leaky gut” hypothesis.  
To evaluate these transcripts in a bigger perspective, a functional enrichment analysis of the ten 
remission transcripts was performed to evaluate which pathways and what interactions were present. 
Figure 3 shows the result of the analysis preformed with open-source Cytoscape software (251-254). 
The partial donut represents the top three reactome pathways these proteins are included in, evaluated 
by number of genes and lowest false discovery rate (255).  
Figure 3 Functional Enrichment Analysis of UC Remission. PPI enrichment = 5.05E-9, indicating 
that there are more interactions between these proteins than would be expected for a random sample of 
proteins. The thickness of the line represents the strength of the evidence, including text-mining, co-
expression and known interactions.  
 
 
The network displays TNF node as a central agent in the cluster as most of the nodes have a strong 
relation to it. Both TNF and the IL1 family signalling are mediated through NF-κB pathway, which 
indicate that this pathway is active in remission. TNF and the NF-κB pathway are previously 
described as important in active UC (99, 256, 257). It was surprising that 6 of the 10 differently 
transcribed genes were implicated in the IL4 and IL13 signalling, as these are considered typical TH2 
cytokines and neither GATA3 (Th2 master transcription factor), IL4, nor IL13 were differentially 
regulated. On the other hand, it could be argued that UC is an atypical TH2 mediated disease and this 




mentioned in the introduction, the partition of IBD into CD as a TH1 driven disease and UC as a TH2 
driven is contentious.  
Overall, the UC remission patients had an increase of pro-inflammatory transcripts associated to NF- 
κB pathway. In addition, mediators of the epithelium and barrier function were differently regulated in 
UC remission patients.   
Investigating the expression difference between MES 1 and 0 was interesting due to the findings that 
MES 0 had better outcome than MES 1 (167, 168). Which genes were differently transcribed between 
the two levels? In paper 1, 11 genes were found to be upregulated in MES 1 compared to MES 0 and 
there was a mixture of proinflammatory (TNF, IL6) and anti-inflammatory (TGFB, IL10) cytokines. 
This increase in cytokines could mirror the minor inflammatory activity that was registered by 
endoscopy. Interestingly, several of the master transcription factors for the central T-cells in UC 
pathology were upregulated. TBX21, GATA3, SPI1, RORC and FOXP3 are the master transcription 
factors for TH1, TH2, TH9, TH17 and Treg. This could be a result of the increased cellularity in the 
mucosa, although this was not reflected histologically as none of these genes correlated with the 
histological score. Nevertheless, this result suggested that there was an increased T-cell differentiation 
activity in MES 1. In a similar study Fukaura et al. find no difference in gene expression between 
MES 0 and 1 regarding master transcription factors, and only IFNG differs between controls and UC 
remission (205).  
The top three reactome pathways gathered from the functional enrichment analysis were IL4 and IL13 
signalling and two unspecific immune pathways (Figure 4). Unlike the remission/normal analysis 














Figure 4 Functional Enrichment Analysis of MES Grade. PPI enrichment = 1.0E-16. The thickness 
of the line represents the strength of the evidence, this includes text-mining, co-expression and known 
interaction. 
 
5.2.3 Relapse biomarkers  
Remission evaluation has had the direction of continuously increasing its resolution to find smaller 
and smaller signs of inflammation. In the beginning the evaluation was solely based on symptoms. In 
the last decade endoscopy has been added as a part of standard evaluation, and now histology is on the 
cusp of being included. Transcriptional markers could come to play a part in this evaluation.  
In paper 3, a regression analysis including 42 variables was made across clinical, endoscopic, 
histological and transcriptional factors to evaluate if one or more of them could predict relapse. The 
median follow-up time was 8 months and the median time to relapse was 6.5 months. 14 of the 41 
included patients experienced relapse during the follow-up time. Of the 42 covariates analysed with 
LASSO regression, 8 covariates had non-zero coefficients and thus a potential predictive ability. Of 
these eight, three were excluded due to too low coefficients and the five remaining were assessed with 
a univariate regression model. IL33, IL1B, MES and UCCS had increased risk for relapse with higher 
levels, while IFNG displayed reduced risk with higher levels. Worth remembering is that a higher 
level i.e ΔCT value, means less actual mRNA transcript in the sample. As there were transcripts with 
opposing effects two ratios were created, IFNG:IL1B and IFNG:IL33. Of these, IFNG:IL33 performed 
better with a higher odds ratio and p-value. The beneficial ratio category had relatively lower ΔCT of 
IL33 and higher of IFNG. An optimal cut-off value was found by ROC analysis and Youden index 
resulting in a specificity of 92.6% and a sensitivity of 57.1% with an AUC of 76.5. With this cut-off 
the PPV and NPV were 80% and 80.6%, respectively. The univariate cox analysis showed that 
patients in the low ratio category had 5.3 (95%Cl = 1.8-15.4) times increased risk of experiencing 




twelve months follow-up. About 25% in the low ratio category had not experienced a relapse 
compared to 75% in the high category group.  
Figure 5 Survival plot of the IFNG:IL33 ratio. Kaplan-Meier plot illustrating the difference in 
survival probability between a high and low ratio of IFNG:IL33 and tested with a log-rank test. Dotted 
lines represent 12 months survival. 
 
 
This ratio has not been previously described as a biomarker for relapse. The results indicated that in 
this remission setting, the presence of IL33 was protective. IL33 is described to be pleiotropic, and 
previous papers report it to be normalized in remission (111, 258). In paper 1, IL33 was found to be 
upregulated in UC compared to non-IBD and to be upregulated in MES 1 compared 0. The 
explanation for this was not clear, but likely, it reflected the dualistic properties and the location 
specific effects of IL33. The immunohistochemistry analysis showed IL33 expression in lamina 
propria mononuclear cells, which could be macrophages. Seo et al. found that IL33 switches M1 
macrophages to the more tolerogenic M2 subtype. Therefore, in the context of remission and low to no 
inflammatory mediators present, reduced IL33 could result in a more pathogenic macrophage 
population. The finding that IFNG was pathogenic was in line with the current knowledge but it has 
not been described as a predictor of relapse (259, 260). IFNG and IL33 do not show any predictive 




Although MES came up as non-zero covariate it was not significant in a univariate model (Odd ratio 
2.75, 95% CL:0.86-8.80). This was likely due to a power issue as MES has been described to be 
predictive of relapse in larger studies (167). Histology was evaluated as a continuous score, and 
categorically as active or in remission, but with two different cut-offs (Strict and Relaxed, see Paper 
2). Interestingly, the histologic evaluation did not show ability to predict relapse, regardless of indices 
applied. Geboes remission category did come up as a non-zero variable but had an infinite coefficient 
and a high p-value. Histology has previously been reported to be predictive of relapse (180, 261). A 
probable explanation was the high variability in the histologic assessment, which could mask any 
potential predictive ability. With a central reader approach the results might have been different.  
In summary low ratios of IFNG and IL33 were predictive of relapse, while MES and UCCS were 
limited by power issues and histology was not predictive of relapse.   
6 Conclusion and implications 
6.1 Conclusion 
Aim 1: To characterize mucosal transcript of UC patients in clinical remission 
- The remission mucosa was dominated by transcripts of pro-inflammatory mediators such as 
TNF and IL1B, while the anti-inflammatory cytokine TGFB1 was down regulated. The gene 
expression difference between the endoscopic grade 0 and 1 was dominated by the master 
transcription factors for several T-helper cells as well as by a mixture between pro-
inflammatory and anti-inflammatory cytokines.  
Aim 2: To evaluate the reliability of the three most applied histologic indices in patients with 
endoscopy defined remission. 
- The reliability of histology was moderate for all the top three histologic indices and none of 
the indices were preferable with regard to test characteristics. The experience of the 
pathologist had a greater impact on reliability than the indices. Although there was a 
difference in accuracy between the pathologists the precision was similar.  
Aim 3: Investigate if any clinical and histological factors and/or gene transcripts can predict 
relapse/remission..  
- A ratio of IFNG and IL33 could predict relapse, while histology could not. Symptomatic, 
endoscopic and histologic evaluations did not show a significant ability to predict relapse. In 
the case of endoscopy, it could have been due to lack of power.  
 
6.2 Clinical implication 
UC is a severe chronic disease that is debilitating for the patient and is inflicting substantial health-
care costs on society. Improved management by precision medicine will most likely benefit the patient 
by reducing the frequency of relapse through a more accurate use of medication. To achieve this, 




Regarding histology’s role in the remission definition, the present data could not warrant its inclusion. 
The current methods of evaluation were too prone to high variance resulting in an insensitive and 
inaccurate result. Histology could be used as an aid in the surveillance of the disease, as it could detect 
inflammation where endoscopy could not.  
Precision medicine refers to the “tailoring of medical treatment to the individual characteristics of 
each patient” (262). There is evidence for biomarkers that can stratify patients according to the future 
course and outcome of disease (190, 263) and biomarkers that indicate safe de-escalation of treatment 
(202, 264). The next step in precision medicine will be to accurately assess the risk of imminent 
relapse in UC patients. The current surveillance algorithm includes symptoms, endoscopy, and faecal 
markers. In the future, transcriptional biomarkers might be included due to the disease-specific and 
objective nature of these markers. The feasibility of using mucosal markers is quite good as there is 
little additional work in taking an extra biopsy for transcript analysis during endoscopy.  
These steps will take UC treatment closer to achieving a precise and accurate evaluation of the 
remission status. In a possible future, patients could receive tailored drugs and follow-up regimes 
based on specific risk factors, when diagnosed. Patients with certain factors could be given a more 
intensified follow-up program with regular endoscopy including mucosal transcript analysis to prevent 
relapse or neoplasia. For other patients, a more relaxed program might be appropriate, where quarterly 
faeces analysis could be sufficient.  
6.3 Research implication 
The immunological profile found in the present study was on transcriptional levels. To reveal the 
mechanisms and the wider implication of these findings it will be necessary to investigate associated 
genes as well as validating these findings on a protein level. Post-translational modification can 
change the protein expression in such a way that it would not reflect the transcript findings. 
Identification of the cell population expressing the cytokines in question, is also of interest. To put the 
pathology behind UC in a bigger picture, a “system biology” approach is necessary. In such an 
approach, data from different branches of biological research such as transcriptomics, proteomics, 
metabolomics and epigenomics are integrated. Combined with machine learning this could lead to 
investigating biology in unprecedented ways.  
The predictors of relapse should be validated in a prospective study where patients in the low ratio 
group will have escalated treatment to prevent relapse. The ratio should also be investigated with a 
multi-omics approach in order to elucidate the cause of predictive abilities. 
Histology has great potential as an adjuvant to clinical decision making but is limited by its subjective 
nature of the evaluation. To reduce the subjectivity, future research should focus on how to optimize a 
central reader approach, such as standardization of collection, preparation, and digitalization. Also, 
with these things in place, a new and promising possibility opens up in artificial intelligent image 
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Mucosal gene transcription of ulcerative colitis in endoscopic remission
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ABSTRACT
Aim/Objective: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. In UC, a wide range of
criteria are used for disease remission, with few studies investigating the differences between disease
remission and normal control groups. This paper compares known inflammatory and healing media-
tors in the mucosa of UC in clinical remission and normal controls, in order to better describe the
remission state.
Method: Mucosal biopsies from 72 study participants (48 UC and 24 normal controls) were included
from the Advanced Study of Inflammatory Bowel Disease (ASIB Study), Arctic University of Norway,
Norway. Clinical remission was defined as Mayo clinical score  2, with endoscopic subscores of  1.
Targeted gene transcription analyses were performed using hydrolysis probes and SYBR-green.
Results: Among the mucosal transcripts examined, 10 genes were regulated in remission versus nor-
mal controls, 8 upregulated pro-inflammatory transcripts (IL1B, IL33, TNF, TRAF1, CLDN2, STAT1, STAT3
and IL13Ra2) and 2 downregulated (pro-inflammatory TBX21 and anti-inflammatory TGFB1). In total, 14
transcripts were regulated between the investigated groups. Several master transcription factors for T-
cell development were upregulated in patients with Mayo endoscopic score of 1 in comparison to 0.
Conclusions: The mucosa of UC in clinical and endoscopic remission differs from normal mucosa, sug-
gesting a remaining dysregulation of inflammatory and wound healing mechanisms.
Abbreviations: IBD: Inflammatory bowel disease; UC: Ulcerative colitis; qPCR: Quantitative polymerase
chain reaction; MIQE: Minimum information for publication of quantitative real-time PCR experiments;
5-ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor; mRNA: messenger ribonucleic acid; RNA: ribo-
nucleic acid; DNA: Deoxyribonucleic acid; MES: Mayo endoscopic subscore; FC: Fold change; ECCO:
European Crohns and Colitis Organisation; RIN: RNA Integrity Number
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Ulcerative colitis (UC) is a chronic relapsing inflammation of
the colon. In the north European population, up to 0.5% are
affected by UC, with a yearly healthcare cost estimated at
4.6–5.2 bn. Euros [1,2]. The etiology of the disease is not fully
established but the four factors; genetic susceptibility,
immune dysregulation, environmental factors and the gut
microbiome are currently thought to play a central role in
the pathogenesis of UC [3–5]. While only surgery is curative,
immune-suppressive drugs have proved to be the most
effective pharmacological treatment of the disease. In par-
ticular anti-tumour necrosis factor (TNF) therapy has shown
to be crucial in treatment of severe cases [6,7].
The disease activity of UC is cyclical, which means treat-
ment is given when the patient has flare-ups and stopped or
de-escalated when the patient is in remission after short- or
long-term maintenance treatment. The term ‘disease remis-
sion’ is widely used in UC, however, there is no consensus on
what constitutes remission. The latest ECCO guidelines (2017)
suggest a combination of clinical parameters (stool frequency
 3/day with no bleeding) and no mucosal lesions by endos-
copy [8]. The British Society of Gastroenterologys IBD guide-
lines define clinical remission as mayo score 2 and no
individual score  1 [9]. The lack of consensus has given rise
to many different terms such as mucosal healing, histological
remission and deep remission. In clinical studies, the Mayo
endoscopic grade is often used for determining remission,
with scores of 0 and 1 both accepted as ‘remission mucosa’
[10–12]. Although, latest reviews suggests Mayo 0 as treat-
ment target [13]. Unfortunately, there are no studies compar-
ing this two-value score on a translational level and this
represents a knowledge gap. Altogether, these issues make it
challenging for the clinician to evaluate whether a patient is
in disease remission or not.
By investigating the difference between normal and
mucosa in clinical remission, without the distortion of inflam-
mation, we can get a better understanding of immunological
dysfunction in UC, with special emphasis on endoscopic
Mayo score 0 versus 1. Therefore, the objective of this study
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was to describe the colonic mucosa of patients that are in
clinical and endoscopic remission with a focus on cytokine
expression and signaling.
Material and methods
This study is a part of the Advanced Study of Inflammatory
Bowel (ASIB) prospective study at the University Hospital of
Northern Norway, Tromsø. All study participants gave writ-
ten, informed consent. The study and storage of biological
material was approved of by the Regional Committee (REK
Nord ID:2012/1349).
Study populations
Participants with UC according to established diagnostic defi-
nitions [8] were recruited from the ASIB study. An overview
is presented in Table 1. For the remission group, we
recruited primarily patients with moderate/severe disease
who had been treated with anti-TNF. Inclusion criteria: age
between 18 and 80, Mayo clinical score of 0 or 1, with endo-
scopic subscore of 0 or 1. No points were allowed on rectal
bleeding feature and a total Mayo score larger than 1 was
not included [8].
UC active inclusion criteria were: Total Mayo score above
2 and endoscopic subscore of 2 or above [14]. Endoscopic
signs active UC and no inflammation of ileum.
A control group of non-IBD patients screened with colon-
oscopy for colorectal cancer or mild gastrointestinal symp-
toms were included. Criteria for healthy controls where no
diarrhea or other irritable bowel symptoms, as well as a com-
pletely normal endoscopy, with no polyps in sigmoid and no
hyperplastic polyps in rectum lager than 5mm.
Gene transcription measurement
The gene analysis was performed as close to the MIQE
guidelines as possible [15]. Two different qPCR methods
were used (Hydrolysis probe and SYBR-green).
Biopsy preparation
Biopsy collection was done during routine colonoscopies and
immediately immersed in RNAlater (Qiagen N.V, Venlo, the
Netherlands) and kept in room temperature for at least 24 h
prior to storage at -80 C.
RNA preparation
The biopsy sizes were within the range of 3–10mg. The sam-
ple was then homogenized in the MagNa lyser instrument
(Roche Diagnostics, Etterstad, Norge) for 40 s at 6500 rpm.
After the sample was disrupted and lysated it was centri-
fuged for 3min at 13,000 rpm. Total RNA extraction was
done with QiaCube and AllPrep DNA/RNA mini kit (Qiagen
N.V, Venlo, the Netherlands) according to the AllPrep DNA/
RNA mini protocol for animal cells and tissue. Total RNA sam-
ples were stored at 80 C. Total RNA concentrations were
measured with QubitVR 3.0 Fluorometer (Thermofischer,
Waltham, Massachusetts, USA). The RIN values averaged 8.4
(SD 1.7) as measured by an Agilent Bioanalyzer (Agilent
Technologies Inc., Santa Clara, California, USA). cDNA synthe-
sis was done with RT2 First Strand Kit using 0.5ug of
total RNA.
Reverse transcription
Reverse transcriptions for the hydrolysis probe assays were
performed with QuantiNova Reverse Transcription Kit, while,
the SYBR-green assays utilized RT2 First strand Kit according
to manufacturer’s instructions.
qPCR
Levels of mRNA for the selected genes, were determined by
real-time quantitative polymerase chain reaction (qPCR) on a
BioRad CFX connect 96-well thermal cycler (Bio-Rad
Laboratories AB, Hercules, California, United States). The dual
labeled hydrolysis probes (TaqMan) were done with the
QuantiNova Probe RT-PCR Kit (Qiagen); and the SYBR-green
assays were done with the RT2 Profiler kit(Qiagen), all
according to the manufacturer’s instructions.
Thermal cycler protocol
The plates had a positive, negative and genomic control. All
plates were read at standardized threshold values. For the
hydrolysis probe assays a 2-step protocol was used:
Denaturation 95 C for 2min, then [95 C/5 s and 60 C/5 s]
repeated 40 times. All genes were normalized to Beta
Actin (ACTB).
For the SYBR-green assays, a 2-step protocol was used:
denaturation at 95 C for 10min, then [95 C/15 s and 60 C/
60 s] repeated 40 times. All genes were normalized to the
geometric mean between HPRT1 and RPLP0 as recommended
by NormFinder analysis [16].
Primer design
The primers and hydrolysis probes for the experiment were
designed using Beacon Designer v8 (PREMIER Biosoft
International, Palo Alto, USA). To ensure specificity for mRNA,
all probes spanned exon splicing sites and all primers and
probes were run through a BLAST search to ensure
Table 1. Baseline characteristics in ulcerative colitis in clinical remission, active
and in normal controls.
Normal controls UC Remission UC Active
qPCR (SYBR-green)
Number 10 9 4
Gender (M/F) 7/3 3/6 2/2
Age (mean) 56.9 42.6 27.2
Biopsy location 1/9/0 3/4/2 2/1/1
Average endoscopic score 0 0 2.25
qPCR (hydrolysis probe)
Number 24 44
Gender (M/F) 16/8 19/25
Age (mean) 54.5 40.5
Biopsy location 2/21/1 23/15/6
Average endoscopic score 0 0.25
Rectum/Sigmoid colon/Unknown.
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specificity for the mRNA sequence in question. The efficiency
of all assays were measured by analysis of a dilution series
from a biopsy extract (Table S1). Primers and probes were
ordered from Eurogentec, (Kaneka Eurogentec S.A,
Seraing, Belgium).
SYBR-green PCR array
The SYBR-green assays were prefabricated plates that were
ordered from Qiagen with 26 genes picked by association to
TNF, t-cell differentiation and barrier permeability. An add-
itional 3 were selected as reference genes, where 2
were used.
Statistics
Statistics were performed using IBM SPSS Statistics 24 and R
statistics version 3.4.3 and Rstudio Version 1.1.442.
Assumption of normality was investigated with histograms,
Q-Q plots and Shapiro–Wilks test. Two-way ANOVA models
were used to compare groups. Genes that did not display
normal distribution were evaluated with appropriate non-
parametric tests. To investigate the difference between the
groups in we did a linear model to find the coefficient
between clinical status groups and then calculated fold
change (FC ¼ 2-DDCT). Benjamini Hochberg correction for
multiple comparisons was calculated. All tests were two-
sided and p-values below .05 were considered significant.
The adjusted model used in the hydrolysis probe data set
was diagnosis (UC or normal) by gene, adjusted for gender,
age, Geboes score and endoscopic score. The same method
was applied to the SYBR-green dataset but because of power
issues the model was reduced to only include clinical status,
age and gender.
Results
Overview of the differently expressed genes
In total, 22 gene transcripts were analyzed using a hydrolysis
probe (Table 2). Between UC remission and controls five of
these genes, TBX21, TNF, IL1B, TGFB and IL33 showed a sig-
nificant difference (Figure 1). Twenty-nine genes transcripts
were analyzed with SYBR-green (Table 2) assays on three
groups (UC active, UC remission and controls). Between UC
remission and controls five genes (TRAF, CLDN2, IL13RA2,
STAT1, STAT3) were differently expressed (Figure 2). These
five and an additional five were regulated between UC active
and controls with the SYBR-green assays (ADAM17, CASP8,
CHUK, DEFB1, TFF3; Figure 3). Overview of differently tran-
scribed genes between clinical remission mucosa and con-
trols in regard to gene relationship are shown in Table 3.
Hydrolysis probe assays: Difference in mucosal
transcripts between clinical remission and
normal controls
Patients in clinical remission had 3.2-fold higher transcription of
IL1B than control (p¼ .001). IL1B also displayed a gender differ-
ence where males had a fold change of 5.3 compared to 2.2 in
females. IL33 and TNF were up-regulated in clinical remission
compared to control; FC¼ 1.7 (p¼ .02), and 2.0 (p¼ .01),
respectively. TBX21 and TGFB1 were less expressed in clinical
remission patients, FC ¼ 0.2 (p< .001) and FC¼ 0.7 (p¼ .038),
respectively. Almost all genes were significantly associated with
the endoscopic subscore, see Table S2. Benjamini–Hochberg
correction for multiple comparison sets a p-value of p< .01.
SYBR-green assays: Mucosal transcripts differs between
clinical remission, active disease and normal controls
Ten genes were significantly different when comparing active
disease and control with the SYBR-green assays (Figure 3). Of
these 10, five genes were still upregulated when remission
mucosa was compared to control (Figure 2). The following
genes were differentially expressed: Adam17 (p¼ .013), CASP8
(p¼ .001), CHUK (p¼ .006), CLDN2 (p¼ .016), DEFB1 (p¼ .029),
IL13RA2 (p< .001), STAT1 (p¼ .007), STAT3 (p¼ .016), TFF3
(p¼ .001), TRAF1 (p¼ .001), see Table 3. Benjamini–Hochberg
correction for multiple comparison sets a p-value of .019. The
interaction term between gender and clinical status was sig-
nificant for STAT1, CLDN2 and TRAF1.
Difference in subscore Mayo 1 and 0
When comparing the clinical endoscopic Mayo score of 1
and 0 we found several genes that were differentially tran-
scribed. Following adjustment for age and gender, 11 genes
were found significantly up-regulated in Mayo endoscopic
subscore 1 compared to subscore 0 (Figure 4).
Discussion
The main findings of the present study are 1: We found 10
differentially transcribed genes between patients in clinical
remission and subjects with normal mucosa. Of these 10
genes, eight pro-inflammatory were up-regulated and two
(pro-inflammatory TBX21 and anti-inflammatory TGFB1) were
Table 2. All tested genes by the analysis method.
Method Cytokines Transcription factors Receptors Reference genes Others
qPCR hydrolysis probe IFN, TNF, TGFB1, IL1B,
IL4, IL6, IL8, IL10, IL13,












PPIA, RPLP0, HPRT1 OCLN, TFF3, ADAM17,
PTK2, CASP8, CCR2,
DEFB1, BCL2, CLDN2
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down-regulated (Figures 1 and 2). 2: In addition, we found
several T-cell transcription factors to be up-regulated in
Mayo subscore 1 in comparison with 0 (Figure 4). The differ-
ence in transcription was small for most of the tested genes,
this could be explained by the lack of active inflammation
that could distort the results. As expected, the pro-inflamma-
tory genes were up-regulated in active UC and the inhibitory
genes, such as CHUK, were down-regulated.
The transcriptional difference between Mayo subscore 0
and 1
Our results show a difference in transcription between the
Mayo endoscopic score (MES) of 0 and 1. Previous papers
have shown that a MES of 0 gives a favorable outcome in
relation to clinical remission rates [17–19]. All genes that
were differentially transcribed were up-regulated in MES 1.
Interestingly, most of the up-regulated genes were transcrip-
tion factors for T-cell differentiation: TBX21, GATA3, SPI1,
RORC, FOXP3 that are central transcription factors for TH1,
TH2, TH9, TH17, and Treg, respectively. This finding indicates
that the t-cell differentiation of these linages of are still
active in the Mayo subscore 1 score. Worth noticing is that
TBX21 is down-regulated in the remission mucosa compared
to normal mucosa, but up-regulated in the MES 1 compared
to MES 0. This could be because of medication suppressing
t-cell development and the slightly increased cellularity one
expects to find in mildly inflamed mucosa. The up-regulation
the anti-inflammatory cytokines TGFB and IL10 however sug-
gest a counter-balanced inflammatory response. This is sup-
ported by the lack of TNF expression in MES 1. Still, it is
important to notice that TGFB for the two groups (Mayo 0
and 1) as a whole was less expressed than in the normal
group. To our knowledge this is the first investigation of
gene transcript difference between Mayo subscores 0 and 1.
This may have clinical implications for determining when to
de-escalate treatment in UC in clinical remission. However,
further investigation is warranted.
TNFR1/NF-Kb pathway
The results show that TRAF1 has increased expression in
both clinical remission and active UC mucosa, when com-
pared to normal mucosa. This finding can be interpreted
as an attempt to ameliorate the inflammation and reduce
NFKB signaling. TRAF1 is a TNF receptor regulatory protein
and is related to cell apoptosis/necroptosis and inflamma-
tion. It is suggested that the ratio between TRAF1 and
TRAF2 is important for the effect TNF has on T-cell expan-
sion [20]. Where TRAF1 is a negative regulator and TRAF2
is positive. This was confirmed in a study of TRAF1 defi-
cient mice, where an increased response to TNF and
Figure 1. Volcano plot demonstrating differentially regulated genes between clinical remission and normal controls when adjusted for age, gender, endoscopic
score and Geboes score. TBX21 is analyzed with a nonparametric method (Mann–Whitney U-test). Genes analyzed with hydrolysis probe. All named genes are sig-
nificant (<.05) and genes on the left-side are down-regulated, conversely, genes on the right-side are up-regulated.
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higher T-cell proliferation was shown [21]. It is also sug-
gested that TRAF1 has opposite actions depending on
cleavage by CASP8. A full length TRAF1 is pro-cell survival,
whereas a cleaved TRAF1 is pro-apoptotic when in a
stimulated TNFR1 context [22]. Our findings are in line
with other reports that TRAF1 is up-regulated in active UC
and inhibit NFKB signaling [23].
Our results suggest that CASP8 is up-regulated in active
UC and not in clinical remission. CASP8 regulates apop-
tosis/necroptosis and is inhibited by NFKB activation. Our
result is surprising as one would expect prolonged
immune cell life to be beneficial in order to deal with
infection. On the other hand, it could be a result of an
attempt to down-regulate the inflammation. Up-regulation
of TRAF1 could give a higher activation of CASP8 as
TRAF1 regulates NFKB activation and may thereby remove
inhibition for CASP8 activation, as mentioned earlier.
Previous papers have reported no difference in CASP8
between control and UC [24].
The results of our analysis show that even in non-symp-
tomatic and non-inflamed mucosa TNF is still up-regulated.
TNF is one of the central cytokines in inflammation and acts
as a pro-inflammatory cytokine. The up-regulation of TNF in
clinical remission UC patients could be due to the cyclic
nature of inflammation. Previous results are conflicting on
the presence of TNF in remission mucosa [25,26]. This could
be a result of different definitions and lack of consensus on
what constitutes remission.
JAK-STAT pathway
Our study showed that STAT1 and STAT3 are up-regulated
both in clinical remission and active UC when compared
with normal mucosa, in line with previously published data
[27,28]. STAT1 and STAT3 are a part of the JAK-STAT pathway
which is responsible for several immunological functions and
responses. Interestingly, our findings suggest that these sig-
naling pathways are not just up-regulated in active inflam-
mation, but also in clinical remission. What their functions
are in clinical remission mucosa is difficult to say as they are
involved in both pro- and anti-inflammatory signaling path-
ways dependent on cell type and substrate. Further eliciting
their role in non-inflamed UC mucosa requires further stud-
ies. STAT3-mediated activation of acquired immune
responses plays a pathogenic role in colitis by enhancing
survival of T cells and by inducing TNF. In contrast, STAT3-
mediated activation of innate responses contributes to the
suppression of colitis by enhancing the mucosal repair and
by inducing mucin production [29]. In either case, thera-
peutic targeting of the JAK-STAT signaling pathway with
tofacitinib shows promising results [30].
Innate immune system
We found that ADAM17 was up-regulated in active UC which
is in keeping with previous research [31]. ADAM17 has been
shown to cleave TNF to soluble TNF and can therefore be
Figure 2. Volcano plot demonstrating differentially regulated genes when comparing Ulcerative colitis in clinical remission to normal controls. Genes are analyzed
with SYBR-green and are adjusted for age and gender. Genes on the left-side are down-regulated and genes on the right-side are up-regulated.
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pro-inflammatory, on the other hand its role in activation of
Erb-B ligands and Notch-1 pathway makes it a contributor to
epithelial regeneration [32]. In addition, ADAM17 cleaves the
IL1B decoy receptor IL1R2 into soluble sIL1R2 which is sug-
gested to have anti-inflammatory effect [33,34]. We could
not detect significant expression of IL1R2 in any of our
groups. Nevertheless, ADAM17 is a key protein in the role of
TNF effects and plays an important role in inflamma-
tory diseases.
IL1B is known to have a pro-inflammatory function in UC
[35,36], and interestingly, the results show that IL1B was up-
regulated in clinical remission mucosa, indicating a subclin-
ical inflammation which could contribute to the cyclical
nature of the disease.
Our results show that IL33 was still up-regulated in clin-
ical remission patients, although its receptor IL1RL1 was
not. The role of IL33 in UC is not clearly defined and it is
likely dependent on the stage of inflammation [37,38]. IL33
has been implicated in intestinal fibrosis and in mucosal
healing and goblet cell restoration [39–41]. Thus, the pres-
ence of IL33 in UC clinical remission may represent
ongoing wound healing/fibrogenesis and not an inflamma-
tory process.
Our findings suggest that TFF3 is expressed more in active
inflammation. TFF3 is a protein secreted to the lumen from
goblet cells in the colon and has a role in protection and
Figure 3. Volcano plot demonstrating differentially regulated genes when comparing active Ulcerative colitis to normal controls. Genes are analyzed with SYBR-
green and are adjusted for age and gender. Genes on the left-side are down-regulated and genes on the right-side are up-regulated.
Table 3. Hydrolysis probes results are adjusted for age, gender, endoscopic
subscore and Geboes score. SYBR-green results are adjusted for age
and gender.
Gene Remission vs. Normal p-value Mayo 0 vs. 1 p-value
Hydrolysis probe
IL1b 1.6" <.001 Ns
TNF 0.9" .011 Ns
IL33 0.7" .019 0.8" .012
TGFb 0.5# .038 0.9" .000
TBX21 2.8# <.001 3.4" .000
IL6 Ns 1.2" .033
IL10 Ns 0.9" .010
TLR4 Ns 0.8" .001
IL1RL1 Ns 1.2" .000
SPI1 Ns 1.0" .004
FOXP3 Ns 1.6" .001
GATA3 Ns 1.4" .000
RORC Ns 0.7" .039
SYBR-green Remission vs. Normal p-value Active vs. Normal p-value
Adam17 Ns 49" .011
CASP8 Ns 2.2" .001
TRAF1 2.2" .006 8,2" .001
CHUK Ns 1.9# .043
CLDN2 2.12" .039 4.3" .005
DEFB1 Ns 2.8" .011
IL13RA2 1.32" .023 2.6" .001
STAT1 1.42" .049 2.3" .002
STAT3 1.49" .024 1.9" .006
TFF3 Ns 29" .001
Up-regulated genes are labelled " while down-regulated genes are labelled #.
For further details see text (Section Results) and Figures 1–3.
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healing of the mucosa. However, an earlier paper reports no
difference in TFF3 expression between normal and UC active
mucosa [42].
In our investigation, we found that TGFB1 was down-regu-
lated in remission patients compared to normal. TGFB1 is
negative regulator of mucosal inflammation, and it is well
known that this cytokine is up-regulated in inflamed mucosa
[43,44]. TGFB1 signals from the receptor to the nucleus
through several proteins called SMAD’s. Previous reports on
the expression on TGFB1 in healthy and remission mucosa
varies from no difference to down-regulated [43,45].
However, changes in TGFB1 expression should be interpreted
with caution due to extensive post-translational modifica-
tions necessary for activation of the TGFB1 protein.
Strength and weakness
The main strength of this paper is its focus on clinical remis-
sion in UC patients, highlighting the found perturbation as
possible central factors in the basic immunopathology of
Ulcerative colitis. There are weaknesses to the study as well:
(A) The study population is clinically heterogeneous in that
participants are in different phases of their disease and on a
variety of medication, making it more difficult to discuss the
mechanics of the pathways affected. However, this makes
our results more clinically applicable to the average UC
patient and not just the un-treated or the anti-TNF naïve
etc.; (B) Only partial compliance with the MIQE guideline for
PCR research as ACTB was sole reference gene. This can
make the fold change results more uncertain, albeit most of
our findings are in line with previous research and later val-
idation showed ACTB to have low inter- and intragroup vari-
ation, thus, introducing little error. (C) Because of the
invasive nature of the sample collection, our control popula-
tion are people referred for colon cancer screening thus
resulting age difference between study groups; (D) The low
statistical power precludes models adjusting for medication,
disease duration, and smoking status etc. (E) Transcriptional
analysis has the inherent restrictions that it does not prove a
functional protein, therefore any interpretation of difference
on a protein level based on at transcriptional levels should
be done with caution, nevertheless, it may serve as a
hypothesis generator for further research. (F) We used two
different methods of detection with qPCR. This is due to cost
and time restrictions. Prefabricated plates saves time as we
do not have to go through the time-consuming process of
designing, optimizing and validating in total 29 new genes.
In our exploratory context we believe this to be an accept-
able approach.
Concluding remarks
In conclusion, we have shown that in clinical UC remission
there is still an ongoing expression of inflammatory
Figure 4. Volcano plot demonstrating differently translated genes between mayo endoscopic score 0 and 1. Analyzed with hydrolysis probe. Several transcription
factors for T-cell development are up-regulated.
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mediators, although it seems to be more balanced towards
mucosal healing. A mucosa with MES 1 transcribes more pro-
inflammatory mediators than in MES 0, which may have clin-
ical impact such as when to de-escalate treatment. Finally,
we found that important transcription factors in the JAK/
STAT pathway are still up-regulated in remission patients.
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Histological evaluation of ulcerative colitis (UC) patients has been debated ever since the
first description of the disease and its role in follow-up has never been fully established.
Recent evidence suggests an added benefit in accuracy when evaluating if the patient is in
remission. Unfortunately, there are several different histological indices, and it is difficult to
compare outcomes where different scores are applied. Histopathological evaluation is
prone to subjective biases, despite the use of indices. In addition, these indices are devel-
oped by expert IBD pathologist, but applied at large, by general pathologist. Therefore, we
evaluated the three most applied histological indices for UC on samples from patients in
remission to compare test qualities and estimate their usefulness to identify remission by
both general and GI specialized pathologist.
Method
Mucosal biopsies from 41 UC patients in clinical and endoscopic remission were collected
as part of a larger study on UC. Three pathologists blinded to the patients’ clinical status
evaluated them using Geboes score (GS), Nancy Index (NI) and Robarts Histopathological
Index (RHI). We calculated the agreement between the pathologists using Inter-class corre-
lation (ICC) and visualized it with ICC-plots and Bland-Altman plots. Association between
clinical factors and histological category were analysed by Fisher’s exact test.
Results
The ICC value for GS, RHI and NI were 0.85, 0.73 and 0.70 respectively. The limits of agree-
ment were ±6.1, ±4.0 and ±1.4, for GS, RHI and NI, respectively. Mayo endoscopic sub-
grade and UC clinical score did not show association with any histological scores. Despite
clinical and endoscopic remission 7–35% of the patients displayed histological inflammation
on a level classified as active disease, depending on the index and cut-off.
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Conclusion
A substantial amount of UC patients in clinical and endoscopic remission display inflamma-
tion on a histological level, but the ability to classify these patients accurately and consis-
tently could be improved.
Introduction
Ulcerative colitis (UC) is a chronic disease of the colon with relapsing-remitting characteris-
tics. The introduction of targeted antibodies, such as anti-TNF, directed against key pro-
inflammatory mediators, has improved patient outcome and lowered colectomy rates [1, 2].
However, the medication is expensive and has serious side effects like lowering the immune
competency against certain infections and cancers [3]. Therefore, finding optimal criteria for
remission is important, not only for the patients’ health but also in a health-care economic
aspect.
There is no universally applied definition of the state of remission, but usually only clinical
or endoscopy-based scores are applied. The current treatment goal is partial Mayo score/
SCCAI�1 and mucosal healing (MH) which is defined by Mayo endoscopic score (MES) of
�1 [4–6]. However, this recommendation is moving towards MH to include only MES/Ulcer-
ative Colitis Endoscopic Index of Severity (UCEIS) of 0 [7].
Histology adds a dimension in the evaluation of remission which can be beneficial. This
was illustrated by a relapse prediction model that included both histologic and endoscopic
activity. The model could predict relapse better than endoscopy alone [8]. Histology can detect
subclinical inflammation despite endoscopically normal/near-normal mucosa and this inflam-
mation increases the risk of an unfavourable outcome, such as relapse or neoplasia [9–13]. The
European Crohn’s and Colitis organization has recently published guidance on this topic [14].
However, the multiple scoring indices for histopathology in UC makes it difficult to compare
the results between papers [15]. In addition, most of these indices lack thorough validation
[16, 17]. Geboes Score (GS), Nancy Index (NI) and Robarts Histopathological Index (RHI) are
the few that are partly/fully validated, and they vary in complexities and features they evaluate
[18–20]. The position paper for ECCO recommends NI for clinical practice and observational
studies. For histology to be of use in determining remission certain criteria must be fulfilled:
A. It must add information of the inflammatory state not otherwise obtained. B. It must reli-
ably and accurately identify these signs. C. The use yields a benefit in patient outcome. This
paper focuses on the two first subjects, but also explores the relationship between histology
grades and clinical parameters.
The US Food and Drug administration now recommends that histopathology should be
included as endpoints in new trials. Therefore, there is an urgent need to define the histopath-
ological remission state so it can be applied in trials and in the clinic. To address this, we evalu-
ated the properties of the three most validated histological indices in a population defined to
be in remission according to the current recommendations.
Material and methods
Study population
This study is a part of the Advanced Study of Inflammatory Bowel disease (ASIB) prospective
study at the University Hospital of Northern Norway, Tromsø. All study participants gave
PLOS ONE Real life evaluation of histologic scores for UC
PLOS ONE | https://doi.org/10.1371/journal.pone.0248224 March 8, 2021 2 / 12
HNF1517-20 and HNF1468-19 The publication
charges for this article have been funded by a grant
from the publication fund of UiT The Arctic
University of Norway The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
written, informed consent. The study and storage of biological material was approved of by the
Regional Committees for Medical and Health Research Ethics, division North (REK Nord
ID:2012/1349).
The selected participants were previously diagnosed with UC according to diagnostic rec-
ommendation [5]. Overview of baseline characteristics is presented in Table 1. Sample collec-
tion was performed at routine endoscopy for patients in remission from August 2013 to April
2016.The most frequent clinical indication being follow-up due to cancer screening and de-
escalation of treatment. Inclusion criteria were age between 18 and 80 with clinical and endo-
scopic remission defined as Mayo clinical score/Ulcerative Colitis Clinical Score (UCCS) of 0
or 1 and Mayo endoscopic score (MES) of 0 or 1. Total Mayo score above 1 or rectal bleeding
was not included. IBD medication was not an inclusion or exclusion factor.
Histology
All biopsies were formalin fixed immediately after sampling and embedded in paraffin. Multi-
ple 3-μm sections were cut with a Micron microtome (HM355S, ThermoFisher, Tudor Rd,
Runcorn WA7 1TA, United Kingdom) and stained with haematoxylin and eosin. In cases of
multiple biopsies from one patient, the highest scoring biopsy was included in the analysis.
Slides were investigated by three pathologists (SWS, SMD and LBR) blinded to the endoscopic
score and biopsy location. SWS and SMD are general pathologists who evaluate 200–300 GI
samples yearly, of which about 20–30 are IBD related. LBR works mainly with GI samples and
sees around 180–360 IBS samples yearly. The final score for a biopsy is the average of the three
pathologists. Two of the pathologists are located at the University Hospital of North-Norway
while the third is located at Herlev Hospital in Denmark. SWS and LBR evaluated the slides
using white light microscopy, while SMD evaluated the slides digitally, scanning them with
Pannoramic 250 Flash III (3DHISTECH Ltd. Budapest, Öv u. 3, 1141, Hungary) at 40x with
CaseViewer 2.3. In order to evaluate for intra-rater variability and explore the difference
between light microscopy and digital microscopy SWS evaluated the slides a second time digi-
tally with a 2-month interval. All pathologists were sent a scoring protocol to improve coherent
rating.
The definition of remission across the three indices is not set, different studies have used
different cut-offs. GS range from 13 to 7 (Table A of GS continuous vs original Table A in S1
Appendix) and RHI from <6 to�1 [21–26]. While the developers of NI suggest that�1
should be the cut-off, 0 is also applied in some papers [27]. As the cut-off values are debatable,
it is of interest to explore the impact these definitions would have on a population in clinical/
endoscopic remission. Therefore, we defined two separate definitions of histological remission,
Table 1. Baseline characteristics.
UC remission
Number of patients 41
Gender(M/F) 16/25
Age(mean) 43
Biopsy location (Rectum/Sigmoid/Other) 22/13/6
Average endoscopic score (MES) 0.24
Average clinical score (UCCS) 0.15
Median Robarts Histopathological Index 1
Median Nancy Index 0
Median Geboes Score 4
Average Disease duration 8.8 years
https://doi.org/10.1371/journal.pone.0248224.t001
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one strict and one relaxed. To be in line with previous research and to exclude mucosal neutro-
phils and basal plasmacytosis, the strict cut-off was GS <7, RHI <4 and no points allowed for
neutrophils in neither epithelium nor lamina propria and NI = 0 [14, 27–30]. The relaxed cut-
offs for remission for NI and RHI are the developer’s recommendation (NI<2, RHI <6). For
GS, the relaxed cut-off is widely applied (GS <13) [30].
Statistics
All statistics were performed with Rstudio Version 1.2.5019. Inter/intra-rater calculation was
done with the “irr” and “KappaGUI” packages. Inter-rater on ordinal/continuous variables
was performed with two-way random, average score, intraclass correlation coefficient (ICC)
for consistency (C,3). Intra-rater was performed with two-way random, single score ICC for
absolute agreement (A,1). On categorical variables Fleiss’ kappa was applied and evaluated
according to Landis et. al: < 0: Poor agreement, 0.01–0.20: Slight agreement, 0.21–0.40: Fair
agreement, 0.41–0.60: Moderate agreement, 0.61–0.80: Substantial agreement, 0.81–1.00:
Almost perfect agreement [31]. Bland Altman plots were calculated with mean squared error
according to method proposed by Mark Jones et.al [32]. All scores were standardized by divid-
ing them on their theoretical max and then transformed with square root because of skewness
in the raw data. The standardization makes limits of agreement (LOA) directly comparable.
We investigated systematic rating differences between raters with Kruskal-Wallis rank sum
test. If significant, we made a sub-analysis to identify which graders were different. The sub-
analysis was performed as pairwise comparisons using Wilcoxon rank sum test with multiple
comparison adjusted p-values (Benjamini and Hochberg). Relationships between two dichoto-
mous variables was assessed with chi-square test or Fisher exact test, dependent on group
sizes. These statistical tests were performed with “rstatix” package for R.
Results
In total 41 biopsies from 41 UC patients in clinical and endoscopic remission were evaluated
by two general pathologists and one GI-specialized pathologists using all three scoring indices.
Only five biopsies were evaluated as 0 by all three pathologists across all three indices. Median
scores for indices were 7, 4 and 1 for GS, RHI and NI, respectively. Between 7 and 15% of all
the samples still exhibited histological activity to such a degree that they would be classified as
active disease with a relaxed histological remission definition (GS<13, R<5, N<2). With a
stricter remission definition, the share of active disease increases to between 22–32% of all
samples (GS<7, R<4, N<1). There was a systematic difference between the three pathologists,
where LBR rated higher on average than SWS and SMD with GS, but with a similar standard
deviation (S1 Table). This was significant in a Kruskal-Wallis rank sum test for both GS and
RHI (S1 Fig and S2 Table)
Agreement between raters
The inter-rater ICC value for the features vary from poor(<0.50) to excellent (>0.90) accord-
ing to the classification suggested by Koo et al. (Table 2) [33]. Features describing severe
inflammations are over/under-estimated due to small sample size for those features. Only GS
achieves an agreement of good, while RHI and NI achieves moderate agreement. The intra-
rater evaluation displayed better results, as the final score for the three indices ranged from
good to excellent (0.78–0.92, Table 2). Fig 1 is an ICC plot illustrating inter-rater agreement
between raters for each slide on the Final score for each index. Modified Bland-Altman (BA)
plots displayed the limit of agreement as ±0.53, ±0.59 and ±0.35 for GS, NI and RHI, respec-
tively (Fig 2). If transformed back to the original values it corresponds to ±6.1, ±1.4 and ±4.0.
PLOS ONE Real life evaluation of histologic scores for UC
PLOS ONE | https://doi.org/10.1371/journal.pone.0248224 March 8, 2021 4 / 12
There is a tendency of higher agreement in the extremes of the scores, albeit not a big
difference.
Remission aid and clinical application
Next, we evaluated the inter-rater properties with two different cut-offs for remission, relaxed
(GS<13, RHI<5, NI<2) and strict (GS<7, RHI<3 and NI<1). The latter definition resulted
in a doubling of patients defined with active disease with GS and NI but no change in RHI (S2
Fig). Both cut-offs showed similar kappa values, from fair to moderate agreement (Table 3). NI
and RHI performed slightly better than GS with strict cut-off.
Thereafter, we investigated if there was a difference between high (MES = 1 and UCCS = 1)
and low (MES = 0 and UCCS = 0) endoscopic and clinical grade and the histological category
(Active or Remission). Neither clinical grade, nor endoscopic grade showed significant depen-
dence with the histological category, regardless of strict or relaxed cut-off (S3 Table).
To control for potential confounding factors, we investigated difference in histology score
by their biopsy location and IBD medication. The distribution was rectum (n = 22), sigmoid
(n = 13), and other (n = 6). The Kruskal-Wallis test showed no significant difference between
the different locations (S3 Fig) and the Wilcoxon rank sum test showed no effect of different
medication on the histological scores (S4 Table).
Discussion
This observation study evaluates the performance of the three most validated histological
scores for UC in a remission setting. The main findings are a poor to excellent inter-rater
agreement between the three histological scores, as well as a fair to moderate inter-rater agree-
ment for determining remission. The patients were defined as remission patients according to
Table 2. ICC values for histological feature agreement.
Geboes Score ICC Inter ICC Intra N. patient�
Grade 0 Structural architectural changes 0.65 (0.42–0.80) 0.95 (0.91–0.97) 26
Grade 1 Chronic inflammatory infiltrate 0.83(0.71–0.90) 0.78(0.62–0.88) 26
Grade 2A Eosinophils 0.65 (0.42–0.80) -0.04(-0.33–0.26) 15
Grade 2B Lamina propria neutrophils 0.77(0.61–0.87) 0.89(0.80–0.94) 4
Grade 3 Neutrophils in epithelium 0.89(0.81–0.94) 1.00 4
Grade 4 Cryptdestruction -0.03(-0.73–0.42) 0.00 (-0.30–0.30) 3
Grade 5 Erosion/ulcus 0.10 (0.51–0,49) NA- 3
Final Grade 0.85(0.75–0,91) 0.96 (0.93–0.98) 35
Robarts Histopathological Index
Chronic Inflammatory Infiltrate 0.83 (0.71–0.90) 0.77(0.62–0.87) 26
Lamina propria neutrophils 0.77(0.61–0.87) 0.79(0.64–0.88) 4
Neutrophils in epithelium 0.89(0.81–0.94) 1.00 4
Erosion/Ulceration 0.09(0.53–0.48) NA- 3
Final Grade 0.73(0.54–0.85) 0.96(0.93–0.98) 26
Nancy Index
Chronic inflammatory cell 0.42(0.02–0.67) 0.38 (0.10–0.61) 5
Acute inflammatory cells 0.79 (0.64–0.88) 0.86 (0.75–0.92) 10
Ulceration -0.04(-0.74–0.41) NA 2
Final Grade 0.70(0.50–0.83) 0.86(0.75–0.92) 13
�Number of patients with a score >0.
https://doi.org/10.1371/journal.pone.0248224.t002
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the current guidelines (i.e. clinical and endoscopic remission). Nevertheless, a substantial
number showed histologic inflammatory activity, indicating that histology can unveil inflam-
matory features in a population of patients in remission pre-selected on clinical and endo-
scopic findings. This is in line with previous publications [34, 35].
Compared to previous research, our results show lower concordance between raters. Jairath
et al. had inter-rater ICC of 0.88, 0,86, 0,80 for GS, RHI and NI respectively [36] and Marchal-
Bressnot et al. achieved a ICC value of 0.86 when developing the NI [20]. Mosli et al. achieved
0.82 when developing RHI [19]. The GS method paper applied pairwise Cohen’s kappa and is
not comparable with our results [18]. This difference could be either the result of different
interpretations of scores between our raters or observational errors. All raters were sent the
same scoring protocol (S1 Appendix) to improve coherent rating. It could be argued that a
scoring protocol is not sufficient to ensure coherent rating from general pathologists. We
argue that this the actual situation in most hospitals outside specialized tertiary centres. Thus,
our results show the real-life utility of the scores. By including nothing but patients in remis-
sion, only the lower range of the histologic scales are represented, and this may be viewed as a
“stress test” of the scores for this specific patient group. Consequently, lower inter-rater agree-
ment is expected.
Fig 1. ICC dot plot. The plot illustrates how the Final grade for each slide is scored by the three pathologists. The size of circle indicates how many raters gave the same
score.
https://doi.org/10.1371/journal.pone.0248224.g001
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The results show discrepancies in the severe inflammatory features due to low number of
samples. This is not the case for the eosinophilic feature of GS and the structural architectural
changes features. The number of eosinophils vary greatly between subjects depending on age
and location in a healthy colon [37]. There is no recommendation for what an acceptable cut-
off for eosinophils per segment of colon in UC remission is, and therefore, evaluating this fea-
ture coherently is challenging. Normal variation is also one of the challenges when evaluating
structural architectural changes. Due to the inherent number of histological features included
in this grade such as crypt branching, mucin depletion etc., an overview of it will leave too
many features to subjective interpretations. Especially, since “grade 0.0 is indicated the absence
of any abnormality.”, which is almost never the case. It could be interpreted as disease specific
abnormality, but the need for subjective interpretations on numerous features will challenge
coherency between raters. GS is the only index to include such a feature.
Another subgrade that scored low in the inter-rater score is the Nancy Grade 1, chronic
inflammatory cells. It is difficult to distinguish between moderate to severe amount of chronic
inflammation from acute inflammatory features. There are seldom signs of severe chronic
inflammation without concomitant presence of neutrophils, which defines the criteria of grade
1: “Grade 1 corresponds to the lack of mucosal neutrophils, a pivotal marker of disease activity,
even though moderate or severe chronic inflammation can be present” [20]. Thus, making it a
cause for variation and in many cases redundant.
Our intra-rater evaluation was as good or better than the inter-rater values, except for the
eosinophile feature. Interestingly, there was a clearer difference between the raters than
between modalities (white light microscopy or digitally scanned slides), suggested by the intra-
rater results and the Kruskal-Wallis test (S1 Fig). This indicates that these methods can be used
interchangeably for NI and RHI which does not evaluate eosinophils specifically. The high
intra-rater score and the relatively low inter-rater score indicate that a central raters approach
to IBD-pathology could be beneficial. Standardization of extraction, preparation and scanning
is easier to achieve than extensive training of pathologists.
The modified Bland-Altman analysis identified the same as the Kruskal-Wallis analysis,
that one pathologist rates higher than the two others, nevertheless the standard deviations are
similar (S1 Table). The obvious explanation the IBD-related experience difference between
LBR and the general pathologists. This indicating that experience gives a different understand-
ing of the scores, which seems to effect accuracy but not necessarily precision as the IQR/SD
are similar between raters. The LOA gives the amount the raters can be discordant with the
mean estimated score. The results show better agreement for RHI than NI and GS. This could
be a result of RHI being developed from GS by selecting the features of best agreement. If we
evaluate the absolute LOA scores it shows that all the scores are rather insensitive to minor
Fig 2. Modified Bland-Altman plot. The plot indicating the limits of agreements for the Final grade for each index.
The plot shows less dispersion in the high and low average values, indicating higher agreement. The absolute scores
were standardized then transformed by the square-root. This makes the LOA directly comparable.
https://doi.org/10.1371/journal.pone.0248224.g002





GS, Geboes Score; NI, Nancy Index; RHI, Robarts Histopathological Index.
https://doi.org/10.1371/journal.pone.0248224.t003
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differences, this can explain the drop in agreement when dichotomizing the indices from con-
tinuous variables to “Active” and “Remission”. The agreement appears to be better in the low
and high average scores for all three indices. An explanation could be that it is easier to rate the
extremes of the distribution rather than the middle. This is unfortunate as the cut-off for
remission is in the low-middle of the distribution.
In our data we defined two cut-off values for histologic remission in order to investigate
whether there would be a difference between the two groups in relation to other clinical fea-
tures of importance. There was no dependence between the clinical scores (MES and UCCS)
and histologic category for any of the indices. This is important because a high degree of
dependence between clinical scores and histology would render one of the factors redundant,
as one factor could predict the other. By being independent they can complement each other
Previous studies are conflicting in their report of this relationship between clinical scores and
histologic scores [9, 12, 18, 21, 38].
Strengths and limitations
Our study has several limitations, first and foremost is the different modalities used to evaluate
the slides and the blinding to the biopsy location. The evaluation of eosinophils was challenged
by two factors, one was the blinding of biopsy location to the pathologists and the different
modalities of observation for the intra-rater analysis. Eosinophils significance in UC can be
debated as the two recent indices does not it include it in a separate category and marked
increase in eosinophils without other inflammatory cells suggest eosinophilic colitis and not
UC. Despite the poor intra-rater value for eosinophils, the other categories had good intra-
rater ICC, which suggests that error introduced by scanning the samples is small. Unfortu-
nately, our biopsies are not orientated after collection so the pathologists could not reliably
evaluate basal plasmacytosis, defined as plasma cells between the base of the crypts and muscu-
laris mucosae [39]. Nevertheless, plasma cells fall under the category of chronic cell infiltrate,
which is evaluated in all indices. One could argue that a scoring protocol is insufficient educa-
tion to achieve accurate evaluation by a general pathologist.
Our strengths are the approximation of real-world setting where patients are under differ-
ent treatment regimens and in different clinical settings, making any finding representative for
the IBD remission population.
Conclusion
Our study evaluated reliability of histology scores, in order to estimate their usefulness in clini-
cal decisions. We found that there is a moderate to good agreement between raters when using
three of the most common histological scoring indices, but with a LOA that could be
improved. Unfortunately, when dichotomising the scores into active and remission the agree-
ment falls to fair and moderate. Therefore, without more extensive training or the adoption of
a central raters approach using the current histological indices for deciding remission should
be done with caution.
Supporting information
S1 Fig. Difference between raters. Significant difference between raters were tested with Wil-
coxon rank sum test with Benjamini-Hochberg adjusted p-values.
(PDF)
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S2 Fig. Bar plot. Difference in patients classified as remission or active according to relaxed or
strict definition of remission.
(PDF)
S3 Fig. Histologic score by biopsy location. No difference was found between biopsy loca-
tions.
(PDF)
S1 Table. Descriptics for raters.
(DOCX)
S2 Table. Kruskal-Wallis rank sum test on raters, by indices.
(DOCX)
S3 Table. Fisher exact test between the UCCS and MES scores and histologic category. The
table shows that histological category is independent for whether the sample was collected
from a MES/UCCS 0 or 1 patient. This was true for both Strict and Relaxed category.
(DOCX)
S4 Table. Wilcoxon rank sum test on the effect of medication on histological scores.
(DOCX)
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Abstract 
Background: Despite the continuous search for better treatment and surveillance regimes for 
Ulcerative Colitis (UC), a substantial number of patient experiences relapse. The current 
management usually includes only three modalities: symptoms, endoscopy and faecal calprotectin. 
To detect imminent relapse and improve treatment other modalities could be included such as 
histology and transcriptional biomarkers. This study investigates the predictive abilities of factors 
related to symptoms, endoscopic appearance, histological appearance, and transcriptional assays.  
Method: 41 participants in clinical and endoscopic remission of UC were included in this 
retrospective cohort. Mucosal biopsies were collected for histological and transcriptional evaluation. 
Histology was evaluated by two general pathologists, and a third GI-specialized pathologist refereed 
on disagreement. Targeted gene transcription analyses were performed using hydrolysis probes.  
Results:  Of the 41 participants, 14 experienced relapses during the follow-up time with a median 
time to relapse of 6.5 months (IQR 6.6) .Median follow-up time was 8 months for the study Eight of 
42 investigated variables showed non-zero coefficients in a LASSO regression analysis. Of these eight, 
the best performing factor was a ratio between IFNG and IL33 gene expressions. A univariate cox 
regression analysis showed 5.3 times (95%Cl = 1.8-15.4) higher risk of relapse in a low IFNG:IL33 ratio 
group than in a high group. The IFNG:IL33 ratio performed better than both UCCS and MES in 
predicting relapse. Histologic evaluation could not predict relapse.  
Conclusion: A ratio between IFNG and IL33 gene expression is predictive of relapse and could be a 




Ulcerative Colitis (UC) is a chronic inflammatory disease of the colon, and it is typically characterized 
by a relapsing-remitting course. Previously, the main costs were linked to hospitalization, but the last 
two decades it has shifted towards medication due to arrival of expensive biological agents (1). 
Although, high in costs, biological agents have proved beneficial in lowering colectomy rates and 
maintaining remission (2, 3). Recent studies report that 43% have a relapsing and remitting course 
during the first 12 months following diagnosis, and 16% relapse within 1 year of de-escalation of 
biological treatment. In a 10-year perspective 67-83% relapse dependent on the clinical situation (4, 
5). Therefore, it is of interest to identify UC patients at risk of relapse so that treatment can be 
optimized to ensure longer periods in remission and fewer relapses using minimal but adequate 
therapy.  
There is little knowledge about what initiates a relapse. Most research is focused on targets for 
treatment and to a lesser degree on surveillance markers. The problem with this approach is that it 
does not differentiate between the mechanisms of resolution and initiation of inflammation. Factors 
that can indicate when inflammation is resolved are not necessarily the same as the ones that can 
give an early warning of an impending relapse.  
An initiative by experts under the auspice of International Organization for the Study of Inflammatory 
Bowel Diseases (IOIBD) recommends a set of goals across different modalities in order to achieve 
optimal treatment (6, 7). According to this expert panel only symptoms, endoscopy and faecal 
calprotectin are recommended for surveillance of UC. These three markers can detect manifest 
inflammation, but so far, it is not found that they can detect imminent relapse. 
The aim of the present study was to address this by an exploratory survival analysis on UC patients in 
remission, with factors across four different modalities (symptoms, endoscopy, histology and 
transcripts) in search of potential new biomarkers for relapse. 
 
Material and methods 
This study was a part of the Advanced Study of Inflammatory Bowel (ASIB) prospective study at the 
University Hospital of Northern Norway, Tromsø. All study participants gave a written, informed 
consent. The study, including storage of biological material, was approved of by the Regional 
Committees for Medical and Health Research Ethics, division North (REK Nord ID:2012/1349).  
Study Participants 
41 UC patients in remission were recruited from the Advanced Study of Inflammatory Bowel Disease 
(ASIB). UC was diagnosed according to established diagnostic definitions (8). Patients in clinical 
remission were recruited at three different time points: at a routine follow-up, at a 6-month control 
after initiation of biological treatment or at an evaluation for terminating biological treatment. 
Independent of medication only patients with confirmed remission defined as: UCCS/Mayo clinical 
score of 0 or 1, with mayo endoscopic subscore of 0 or 1, no points were allowed on rectal bleeding 
feature and a total Mayo score larger than 1 was not included (8). The current treatment regime was 
recorded at time of inclusion. The different steroid and anti-TNF treatments where grouped together 
into categorical yes/no variables. Relapse was defined as contact with health-care provider and 
escalation of treatment, regardless if the escalation was an increase in dosage of mesalazin or 
addition of biological treatment.  
Histophatology 
All biopsies were immediately fixed in 10% formalin after sampling and embedded in paraffin. 
Multiple 3-µm sections were cut with a Micron microtome (HM355S, ThermoFisher, Tudor Rd, 
Runcorn WA7 1TA, United Kingdom) and stained with haematoxylin and eosin. Slides were 
investigated by two general pathologists blinded to the endoscopic score and biopsy location. If 
there were disagreements a third gastrointestinal (GI)-specialized pathologist gave the final score. 
Each slide was evaluated with the three most applied histologic UC indices, Geboes Score (GS), 
Robarts Histopathological Index (RHI) and Nancy Index (NI) (9-11). The histological evaluation 
method is further described in a previous publication (12). Histologic strict definition of remission 
was GS <2A.1, RHI <4 and NI = 0 and histologic relaxed definition was GS <3.1, RHI<5 and NI<2   
Quantitative Polymerase Chain Reaction (qPCR) 
Quantification of genes expression was performed as close to the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines as possible (13). The 
geometric mean between HPRT1 and RPLP0 was used as reference gene for the SYBR-Green assays, 
and ActB was used for the hydrolysis probe assays. More detailed description of qPCR method can be 
found in a previously published paper (14). The teste genes were IL1B, IL6, IL8, IL10, IL18, IL21, IL23, 
Il33, TNF, TGFb, IFNG, TLR4, ST2, SPI1, TBX21, FOXP3, GATA3, RORC, ACTB, IL17, IL4. Corresponding 
primer and probes are listed in supplement 1  
Immunostaining 
Endoscopic biopsies from the sigmoid colon of 9 UC patients in remission and 10 normal controls 
were analysed. 
Formalin-fixed, paraffin-embedded 4 µm sections were deparaffinised and rehydrated through 
graded steps of xylene and alcohol. Antigen retrieval solution (DAKO, Glostrup, Denmark) was used 
and the sections were boiled in a water bath for 20 minutes, followed by 20 minutes cooling at room 
temperature. Goat serum 10% was used for blocking (20 minutes) prior to primary antibody 
incubation. Monoclonal antibodies for IL33 [1ug/ml] (anti-mouse, Nessy-1, Enzo Life Sciences) and 
vWBF[1/100] (anti-rabbit, Abcam) were incubated overnight at 4 C. Secondary goat antibodies 
conjugated with alexa555 or alexa647 for rabbit or mouse (Life technologies) were used as 
appropriated at [1/1000] and incubated for 90 minutes at room temperature. Hoechst 33258 (Life 
technologies) was used for nuclear staining. Sections were mounted with Fluoromount aqueous 
mounting medium (Sigma Aldrich/Merck,St.Louis, USA). Isotype and concentration matched 
antibodies were used (IgG mouse, rabbit, Cell signal Technology, Danvars, MA). Tonsillar tissue 
served as positive controls.  
A Zeiss LSM780 CLSM microscope (Carl Zeiss Microscopy, Zena, Germany) was used with the Zen 
2012 software (black edition) for taking images. Three representative images at x20 magnification 
were taken of each section. Nuclear IL33 signal was analysed using the Volocity® 6.3 software 
(Quorum Technologies Inc., Puslinch, Ontario N0B 2J0) using positive fluorescent signal of total 
nuclear area/positive nuclear area. Image processing was performed with Adobe Photoshop CC 
(Adobe System Software, Ireland Ltd, Dublin) with histogram adjustments only applied for whole 
images.   
Statistics 
Missing data were imputed using nearest neighbour averaging method. Variables with more than 
20% missing values were excluded for analysis.  
The data set had more variables than cases which challenge the ordinary approach of 
backward/forward selection for identifying potential predictors, as they run the risk of producing an 
overfitted model (all variables are listed in Table 4 in Supplements 1). To avoid this we applied a 
strategy often used for high dimensional data such as micro-arrays and sequencing data (15, 16). 
To narrow down the number of potential covariates for the model building, a LASSO regression was 
run 10 000 times with different seed each time. This resulted in a range of different penalizing 
factors, which again produces a range of covariates with non-zero coefficients, i.e covariates with 
potential significance. In this exploratory study the lowest penalty i.e the lowest lambda (λ) value of 
the range, was chosen to avoid excluding potential covariates. The LASSO regression was done with 
glmnet package for R  
The non-zero covariant then went through a forward stepwise model selection by AIC and univariate 
cox regression to identify covariates for a relapse-predicting model. In order to not violate the “10 
events pr covariate” rule of thumb two of the most significant variables were transformed to a ratio. 
The optimal cut-off for relapse prediction was determined with a ROC analysis and Youden J 
statistics. This cut-off what used to dichotomize the ratio into a high and a low category, which then 
was analysed with Kaplan-Meier method to evaluate and illustrate difference in relapse-free survival 
between the two categories.  
The calculations were done with Rstudio Version 1.3.1056. Packages used are listed in supplement 2  
Results 
Of the 41 patients in UC remission did 14 experience a relapse during the follow-up period. The 
median remission time was of 6.5 months (IQR 6.6), whilst those who did not experience relapse had 
a median follow-up period of 12 months (IQR 11). A total of 42 variables across clinical, medication, 
histopathological and gene expression categories were evaluated. Among the clinical characteristics 
at baseline there were no statistical differences between those who relapsed and those who did not 
on p<0.05 level (table 1) 
Table 1 Baseline data. Ulcerative Colitis Clinical Score (UCCS), Mayo Endoscopic Score (MES), Geboes 
Score(GS), Nancy Index(NI), Robarts Histopathological Index(RHI) 
Variable Relapse n=14 Remission n=27 p 
Age (y), mean±sd 44.9±12.5  38.7±13.3 0,173 
Sex: female 9(64%) 16(59%) 0,77 
Disease duration (mth) 103±101 96±71 0,978 
Biopsy location 7(50%)/4(28%)/3(22%) 15(55%)/9(33%)/3(11%) 0,593 
UCCS 0.28±0.46 0.11±0.32 0,171 
MES 0.42±0.51 0.14±0.36 0,0524 
GS 5.64±4.4 4.62±4.36 0,456 
NI 0.5±0.75 0.44±0.8 0,725 
RHI 2.0±2.3 1.9±3.6 0,447 
Current medication 
Mesalazin 13(93%) 25(92%) 1 
Steroids 1(7%) 0 0,181 
Methotrexate 1(7%) 5(18%) 0,346 
Anti-TNF agents 10(71%) 17(63%) 0,604 
AzathioprineMCP 6(42%) 11(40%) 0,91 
 
Variable selection 
After 10 000 iteration 8 variables had been identifies as non-zero by LASSO regression (table 2). 
Table 2 Non-zero covariates. Result for 10 000 LASSO iteration. 8 covariates with number of times 






sd IQR se lower.ci upper.ci 
IL33 2987 0,179 0,131 0,229 0,002 0,174 0,184 
Geboes 
Remission 
Relaxed 1204 0,506 0,236 0,320 0,007 0,493 0,519 
IFNG 1135 -0,125 0,042 0,045 0,001 -0,127 -0,122 
UCCS 1115 0,177 0,041 0,023 0,001 0,175 0,180 
IL1B 1085 0,071 0,031 0,044 0,001 0,069 0,073 
MES 1053 0,186 0,084 0,120 0,003 0,181 0,191 
Age 743 0,005 0,003 0,004 0,000 0,004 0,005 
Disease 
duration 3 0,000 0,000 0,000 0,000 0,000 0,000 
 
Disease duration and age were excluded because of small coefficients. The six remaining variables 
were evaluated in univariate forest plot (figure 1) and with forward selection to uncover which of the 
covariates that were best suited for a final relapse model. In the univariate cox regression Geboes 
Remission Relaxed displayed an infinite coefficient due to no events in the active category and was 
therefore removed. IL33, IFNG and MES were the variables with the lowest AIC in a forward stepwise 
regression (Table 3 in supplement 1). The continuous variables were calculated into quartiles. 
Because of the opposite effect of IFNG and IL33 we subtracted the IL33 dCT value from the IFNG dCT, 
corresponding to a ratio (IFNG:IL33) in linear values. The ROC analysis of this ratio resulted in an 
optimal cut off of 4.2, which had a specificity of 92.6% and a sensitivity of 57.1% with an AUC of 76.5. 
With this cut-off the PPV and NPV were 80% and 80.6%  
Figure 1 Forest plot. Displaying the five covariates from variables selected by LASSO regression. 
Reference levels not displayed. MES:Mayo endoscopic score, UCCS: Ulcerative Colits Clinical Score. 
All mRNA values are dCT values against reference gene value. 
 
Figure 2 ROC plot of IFNG:IL33 ratio. The plot displays the optimal cut-off for maximal sensitivity and 




The Kaplan-Meier analysis on the dichotomized the IFNG:IL33 ratio (low ratio <= 4.2 and high ratio 
>4.2) revealed a statistical significant better outcome for participants with high ratio compared to 
the low ratio group (log rank test, p-value of p < 0.001). The one-year cumulative relapse was 26.7% 
in the low ratio group and 74.8% in the high ratio group.  
Figure 3 Survival plot of the IFNG:IL33 ratio. Kaplan-Meier plot illustrating the difference in survival 
probability between a high and low ratio of IFNG:IL33 and tested with a log-rank test. Dotted lines 
represent 12 months survival. 
 
The IFNG:IL33 ratio was a better predictor than both endoscopic score and clinical score (figure 3 in 
supplement. The univariate cox analysis showed 5.3 times (95%Cl = 1.8-15.4) higher risk of relapse in 
the low group than in the high group. In a multivariate model that includes sex, age and biopsy 
location the model, IFNG:IL33 ratio was still significant (HR = 4.9, 95%Cl = 1.6 -15) although, the 
likelihood ratio test was not significant (Χ2(5) =10.75,p=0.06). A ratio of IFNG:IL1B were also 
significant but lower with a lower HR than the IFNG:IL33 ratio (HR = 4.5, 95%Cl = 1.3-16.3). 
As IL33 showed an association to relapse its relationship with its receptor IL1RL1 was investigated. 
IL33 and ILRL1 showed positive correlation, but there was no difference between those who relapsed 
and those who did not, figure 4 in supplement 1. 
Immunostaining confirmed the presence of nuclear IL33 in both UC and normal 
controls. IL33 was present in endothelial cells (as shown in figure 4 costained with vWBF) and 
mononuclear cells in the lamina propria. No intestinal epithelial cells were positive for IL33, neither 
in UC nor in the control group. Statistical analysis did not reveal a significant difference between the 
two groups. Furthermore, no clear difference in IL33 pattern was observed between relapse and 
non-relapse. 
Figure 4 Immunostaining of Ulcerative colitis in remission. Formalin-fixed paraffin embedded 
colonic biospies from patients in UC remission (a-e). Immunofluorescence showing IL-33 (red) and 
nuclei stained with Hoechst (blue). IL-33 is located in the nuclei of cells located in the lamina 
propria(a,b,c), including endothelial vessels as shown in e) with endothelial vessels stained with von 
willebrandsfactor (green). No positive IL-33 cells were seen in the epithelium. Scale bars equal 25µm. 




In this study we found a 5.3 times increased risk of relapse in UC patients with a low ratio between 
IFNG and IL33. There was no apparent difference in IL33 distribution in the mucosa between 
relapsers and non-relapsers. Histology could not predict relapse in our data.  
The IFNG:IL33 ratio has not been previously described as a predictor of relapse in UC. The beneficial 
ratio consists of relatively lower gene expression for IFNG compared to IL33. IFNG is typically 
described as a central cytokine in active CD (17-19), therefore it was surprising to find it as a risk 
factor for relapse in UC remission. Although, some studies have found it to have a role in both types 
of IBD (20-22). In general IFNG is considered to be central mediator in innate immune response, and 
in IBD it is suggested to be produced in NK-cells and ILC1 in order to activate and potentiate 
macrophages (23, 24). A recent study also identifies IFNG as an intestinal vessel disruptor and implies 
it in IBD pathogenesis (23). In a previously published paper no difference in IFNG expression was 
found between UC remission patients and healthy controls (14).  
Relatively low expression of IL33 was protective in our data and in previous literature it has been 
proposed to have dualistic properties(25, 26). It is found to be upregulated in inflamed mucosa 
especially in epithelial cells (27, 28), and it is believed to function as an “alarmin” that rallies the 
colonic immune-defence (29). In contrast, IL33 is thought to ameliorate inflammation through 
macrophage modulation (30), and it is found to be up regulated in remission compared to healthy 
individuals (14). Immunostaining showed no difference in IL33 amount between UC remission and 
normal controls. IL33 positive cells were in the lamina propria, identified as endothelial cells or 
mononuclear cells, this is in line with previous report (27). IL33 in the lamina propria could represent 
an ongoing healing process, as IL 33 and its receptor ST2 has been linked to wound healing and 
fibrosis (31, 32).  
If validated this IFNG:IL33 ratio may server as an early detection warning for patient in remission as 
the median time for relapse for the low ratio group was 7.5 months while the high ratio group never 
reached median time during the follow up. The ratio achieved an adequate sensitivity of 57.1%, but 
with high specificity of 92.6%. Despite the adequate sensitivity the positive predictive value was 
80.0% with a negative predicting values of 80.1% it is indicating that a patient in the low ratio is likely 
to experience a relapse. In the clinical setting where the ratio could aid the clinical judgement the 
high specificity would prevent unnecessary intensifying of treatment, which in turn gives better 
patient care.  
In this study several clinical factors where investigated and none of the following factors showed 
association with relapse: UCCS, MES and histology. UCCS and MES showed potential as they had non-
zero coefficients but ultimately failed to reach significance. This is likely due to a lack of power as 
lager studies have found it beneficial (33, 34). In the case of histology, we have previously reported 
that there is substantial intra-rater variation in histologic evaluation which could mask any predictive 
ability of histologic evaluation (12).  
The strength of this study was the method of detection for the biomarker and the representativeness 
of the participants for the UC remission population. The method for finding the potential biomarkers 
is broad and unbiased which reduce the chance of falsely disregarding results. The participant group 
was heterogeneous in relation to medication, disease duration and age, which made the results 
applicable to a real-world setting. 
The study was challenged by low number of cases as overfitting was a concern and few variables 
could be included in the final model. With a higher number of participants, a better model could 
possibly have been found which might improve the sensitivity and specificity. Furthermore, the 
present study was exploratory only and therefore these findings need to be validated in a second 
dataset, and the usefulness must be further explored in a prospective intervention study. 
Immunostaining on IFNG is a challenge due to low specificity of IFNG-antibodies. This is previously 
reported and the human protein atlas only rate it as “approved” under immunohistochemistry data 
reliability (35-37).  
In conclusion, the ratio between IFNG and IL33 gene expression is a new and promising biomarker for 
predicting disease relapse in UC patients in remission, independent of medication. Further studies 
are needed to validate this finding, and the mechanisms behind this ratio may have interesting 
implication to the pathophysiology of UC relapse.   
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Table 3 Result from forward selection. Suggesting an model based on IL33, IFNG and MES. 
Table A Cox PH fit 
Variable Beta (SE) HR (95% CI) P 
IL33 1.006 (0.31) 2.73 (1.50, 4.97) <0.001 
IFNG -0.49 (0.25) 0.61 (0.38, 0.99) 0.045 
MES 1.20 (0.62) 3.31 (0.98, 11.27) 0.054 
 
Figure 3 KM comparison over the some feature used evaluation of the remission state. The only 
significant is IFNG:IL33 ration, but UCCS shows tendencies suggesting that it could be significant in a 
bigger data set. 
 




Table 4 All covariates tested with the LASSO regreission 
Clinical Pathological Genetical 
Biopsy location Robarts Histopathological 
Index 
IL1B 
Sex Geboes score IL6 
Age Nancy Index IL8 
Disease duration GS Remission Strict IL10 
Anti-TNF treatment RHI Remission Strict  IL18 
MES Nancy Remission Strict IL21 
UCCS GS Remission Relaxed IL23 
Biological medication RHI Remission Relaxed Il33 
Steroids Nancy Remission Relaxed TNF 
Mesalazin  TGFb 
Azathioprine  IFNG 
Methotrexate  TLR4 
  ST2 
  SPI1 
  TB21 
  FOXp3 
  GATA3 
  RORC 
  ACTB 
  IL17 
  IL4 
 
Table 5 Genes with the corresponding primers, probe and tested efficiency.  














































































































































Forward selection MASS v7.3-51.6 
LASSO regression glmnet v4.0-2 
Survival analysis survminer v0.4.8, survival v3.2-3 
ROC analysis pROC v1.16.2 
Impute Impute 1.58 

